Browse Month: December 2017

SST Corporation – Active Pharmaceutical Ingredients (APIs) #exl #pharma

#pharmaceutical suppliers


Active Pharmaceutical Ingredients (APIs)

For more than 50 years, SST has been instrumental in the development of high-quality APIs for major U.S. pharmaceutical companies. We ensure that new products move through the development phases quickly and without issue. In order to maintain marketability and profitability in the changing API market, this kind of assistance is even more critical than ever before and SST is committed to helping customers meet new challenges.

SST thoroughly researches the marketplace and maintains a network of trusted suppliers throughout Europe and Asia that are continually monitored to ensure that they meet current and future client needs, and to prevent patent infringement. Our APIs meet all FDA and compendial requirements. They are delivered to our customers in the manufacturers’ containers with the original labels and manufacturers’ seals and are accompanied by Certificates of Analysis.

For more information on SST products and services, email us or call 844.476.8200.

Pharmaceutical Chemistry BS Degree #spi #pharma

#pharmaceutical chemistry


Pharmaceutical Chemistry—BS

Discover a Challenging and Rewarding Career

Do you have an inquisitive mind? As a youngster, did you pester those around you with countless questions about science or seek out the answers yourself? Channel your curiosity and perseverance into a stimulating career in pharmaceutical chemistry, and your contributions will go a long way in improving the quality of life for many. With a BS in Pharmaceutical Chemistry from Michigan Tech, you will be prepared to apply your training in chemistry to the process of pharmaceutical synthesis and analysis.

Pharmaceutical chemists, or medicinal chemists, work on multidisciplinary teams to formulate, test, and analyze drugs; conduct basic and applied research in chemistry to understand drug compounds; and develop guidelines for the US Food and Drug Administration, reviewing new drug applications from pharmaceutical companies and the processes used to create these substances.

One-of-a-Kind Program

Our degree program in pharmaceutical chemistry will provide you with strong skills in modern chemical techniques, such as computer-aided drug design, and a thorough understanding of biomedical issues. You will explore the molecular basis of biological processes and drug action, as well as the health applications of compounds that affect living tissue.

Chemistry majors learn best in a lab setting. Our degree program will challenge you to reach far beyond classroom chemistry theory and rote experimentation you ll quickly learn your way around our advanced labs and equipment. with the majority of your time being spent on conducting research (independently and alongside faculty) and creatively exploring the real-world applications of biochemistry, drug design, computational chemistry, and more.

About the Program

  • Learn in a supportive environment. First-year chemistry majors stick together in the Studio Lab and study under the same instructor during their first two semesters, at least. You ll develop excellent critical-thinking and lab skills while building lasting rapport with your instructor and classmates.
  • Enjoy the freedom to experiment in the lab. Once you master lab processes and techniques, you ll be let loose to conduct research individually.
  • Increase your employability. Pharmaceutical companies prefer to hire graduates with a research or internship experience. Undergraduate research is emphasized in the department: all faculty members are advancing basic and applied research in chemistry, and all welcome students into their research groups. Our students have garnered internships with high-profile employers including Los Alamos National Laboratory .
  • Get the extra technological edge on your education. You ll use advanced, state-of-the-art equipment in our teaching labs .
  • Learn from creative, enthusiastic faculty who truly enjoy working with students. And smaller class sizes translate to more personal attention. our department s student-to-faculty ratio is 5:1.
  • Our undergraduate degree programs provide excellent preparation for graduate health programs and law school. combining basic science with real-world applications.

Undergraduate Research Opportunities

Our undergraduate degree programs emphasize undergraduate research experiences. All of our faculty members are advancing basic and applied research in chemistry, and all welcome students into their research groups.

Contact the faculty member you are interested in working with to learn more. Specific positions in each lab depend on availability and funding.

Career Pathways

Still considering your career options? Our degree program offers you the flexibility to change your postgraduation plans with ease, if you decide pharmaceutical chemistry isn t right for you. The strong grounding in fundamental chemistry concepts that you will gain provides adequate preparation for an array of chemistry careers.

What could I do with a pharmaceutical chemistry degree?

The pharmaceutical industry employs close to one-fifth of graduates with bachelor s and doctoral degrees in chemistry. Additional employment prospects include academia, the government, and biotechnology companies.

Depending on your career pathway, you may have the choice to work inside or outside of the lab. You could focus on drug design and development, identifying candidates for clinical studies, drug action, drug transport, drug delivery, drug testing, and targeting; or you could spend the majority of your time in an office setting.

An advanced degree is advisable for some research positions. You will be prepared for graduate work in chemistry or biochemistry, or for a program in the health sciences. If you re interested in pharmacy school, a bachelor s degree will give you an edge up during the application process. Our degree program also provides excellent groundwork for careers in patent law.

Where have our graduates found work?

Our graduates have gone on to work in pharmaceutical and chemical manufacturing and forensic science, and have also enrolled in medical/law school and chemistry graduate programs.

DailyMed – DEMSER- metyrosine capsule #pharma #manufacturing #jobs

#aton pharma


Label: DEMSER- metyrosine capsule

DEMSER1 (Metyrosine) is (–)-α-methyl-L-tyrosine or (α-MPT). It has the following structural formula:

Biotechnology #enobia #pharma




The Biotechnology Ph.D. program offered through the Department of Chemical and Biological Engineering is strongly research-oriented with coursework in Principles of Cell and Microbe Cultivation, Biochemistry and Cellular Metabolism, Protein Purification, Molecular Biology, and Biochemical Engineering.

Biotechnology Engineering (Certificate)

The ability to manipulate the genetic content of microbial, insect, animal, and plant cells has led to a variety of commercial applications in medicine, nutrition, materials science, and the environment. New biotechnology-derived pharmaceutical products are gaining FDA approval, and the sequencing of the human genome will lead to tremendous new opportunities in disease prevention. The Biotechnology certificate program gives you the skills employers are looking for to develop today’s products: biochemical process engineering principles, molecular biology practices, and state-of-the-art cloning and expression techniques.

The Bioengineering Certificate program is designed to train electrical engineers in the medical uses of diagnostic imaging instrumentation, biotechnology professionals with training in tissue engineering to develop tissue implants, and mechanical engineers who are well-versed in biomaterials to design artificial joints. The certificate program allows students to focus on biomedical instrumentation, biomedical optics, biomaterials/biotechnology and tissue engineering or other related areas of study.

Through industry-based projects and case studies, the four-course, graduate-level Biotechnology Certificate programs provide you with the fundamentals and practical considerations in the field, including construction of recombinant DNA and the production of enzymes, therapeutic proteins, vaccines and small-molecule primary and secondary metabolites. The curriculum features modern techniques for separation and purification of small and large biomolecules. In addition, production and separation case studies emphasize process economics, GMP, and QA/QC.

Two certificate programs are available. Each certificate requires four courses.

  • Biotechnology: emphasizes molecular biology practices and state-of-the-art cloning and expression techniques
  • Biotechnology Engineering: emphasizes biochemical process engineering principles and state-of-the-art biotechnology production techniques


Department Chair and Professor

Latest The Top 100 Pharmaceutical Companies News #amylin #pharma

#top 100 pharma companies


Latest The Top 100 Pharmaceutical Companies NewsRSS

Maryland Heights, MO, September 04, 2016 –(– According to a new market research report published by iHealthcareAnalyst, Inc. Small Bone and Joint Orthopedic Devices Market 2013-2020, the global small bone and joint orthopedic devices market is estimated to reach USD 5.8 Billion in 2020, expanding at a CAGR of 5.7% from 2016 to 2020. Visit the Small Bone and Joint Orthopedic Devices Mar.

Maryland Heights, MO, September 04, 2016 –(– Self-Care Medical Devices Market 2013-2020 report estimates the global self-care medical devices market to reach nearly USD 15.8 Billion in 2020, at a CAGR of 4.8% from 2016 to 2020 – iHealthcareAnalyst, Inc. Visit the Self-Care Medical Devices Market 2013-2020 report

All three of the major U.S. stock market indexes are up for the year, but the healthcare sector has been left in the dust. Investors de-risked their portfolios from biotech stocks and other drugmakers in January and February, and many healthcare stocks are still struggling to get back to even for the year.

Novartis International AG / Novartis Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Ultibro® Breezhaler® reduced rate of all COPD exacerbations across differ.

Minnesota Attorney General Lori Swanson has asked Mylan to hand over sales data that show why it significantly hiked the price of EpiPens, she said on CNBC. Your Money, Your Retirement, and the 2016 Presidential Election – What changes will you need to make to your portfolio should Hillary Clinton become president? What happens to your investments should Donald Trump become president? Join us on S.

After a promising kick off, Novartis is raising doubts about the future of its CAR-T program with its decision to dissolve and reintegrate the cell and gene therapy division into its immuno-oncology effort. Yes, you read that correctly: despite exciting progress. This awesome article UPDATE: Future of CAR-T shaken by Novartis R D Shuffle appeared first on Be kind and don’t c.

// €70-75,000 plus benefits: Square One Pharma: Role: Our client is recruiting a Sales Specialist for detection products located in Eastern Germany. Key Responsibilities: Supporting and compete Eastern Germany, Berlin, Potsdam, Jena from Job Search RSS Cet article #jobs #lifescience Square One Pharma: Sales Specialist Detection Products est apparu en premie.

Tecentriq could be Roche s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is. This awesome article Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success appeared.

Arizona Cardinals invite you to meet the players Tuesday September 6th. Peoria, AZ (PRWEB) September 02, 2016 Come join the Arizona Cardinals and Pro Player Health Alliance this Tuesday to kickoff the 2016 NFL season. Meet Rookie of the year David Johnson, Voice of the Cardinals Ron Wolfley, newest Member of Cardinals Ring of Honor Roy Green and many more current players including special guest s.

ALBANY, New York, September 2, 2016 /PRNewswire/ — The heparin market in Europe is rather consolidated, with the Sanofi, Aspen, Pfizer, and Leo Pharma accounting for over 65% of the market in 2015. In a new study, Transparency Market Research (TMR) has found that Sanofi is the clear leader in the Europe heparin market, enjoying a 47.5% share in 2015. Increased global sales of Lovenox can be attr.

The cell and gene therapy unit back will be reintegrated into the main business Novartis says, denying it has turned its back on CAR T therapies.

PUNE, India, September 2, 2016 /PRNewswire/ — Global Blood Transfusion Industry Report 2016 market research provides industry overview and analysis with 2021 Blood Transfusion market forecasts as well as company profile, product picture and specification with capacity production, price, cost, production value and more for major manufacturers. Complete report on Blood Transfusion market spread a.

IRVING, Texas, Sept. 2, 2016 /PRNewswire/ — Alliance Family of Companies is having another tremendous year, according to CEO Justin Magnuson. Alliance ranked No. 177 overall, 16th for Top Health Companies, and 11th for Top Texas Companies on the 2016 Inc. 5000 List. The company will celebrate its ranking on this prestigious list at the upcoming Inc. 5000 Conference Gala on Oct. 18-20. now sells product dedicated to fighting vitamin D3 deficiency Boca Raton, Fla (PRWEB) September 02, 2016 Cubic Pharmaceuticals, a company dedicated to the development and distribution of a variety of medicinal products, announced that its Cubicole D3 supplement is now available for purchase through Cubicole D3 is geared toward protecting individuals from the possible harmfu.

Maryland Heights, MO, September 02, 2016 –(– Electrophysiology Devices Market 2013-2020 report estimates the electrophysiology devices market to reach nearly USD 5.2 Billion in 2020, at a CAGR of 8.9% from 2016 to 2020 – iHealthcareAnalyst, Inc. Visit the Electrophysiology Devices Market 2013-2020 report The glo.

Wakefield, RI, September 02, 2016 –(– ChartWise Medical Systems, Inc. (, the award-winning industry leader in Computer-Assisted Clinical Documentation Improvement (CACDI) software, is pleased to announce the appointment of Tom Emberson to the position of vice president of sales and marketing. In this role, Emberson will work to uncover new opportunities to further e.

PUNE, India, September 2, 2016 /PRNewswire/ — adds “Iron Deficiency Anemia – Pipeline Review, H2 2016” market research report complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and develo.

LAGUNA HILLS, CA–(Marketwired – September 02, 2016) – Itonis, Inc. (OTC PINK: ITNS) Itonis is pleased to announce that it has signed an agreement with Comcast Spotlight Washington to provide cable TV and digital video advertisements for its Emesyl® anti-nausea Homeopathic product. The initial 4-week campaign in the DC market starts on September 5, and will run through October 2, 2016 with a n.

Teva Pharmaceutical Industries Ltd. had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated Thursday by a U.S. agency, a further blow to its bid to block generic versions of a drug that accounts for 20 percent of its revenue. The Patent Trial and Appeal Board sided with Mylan NV and Amneal Pharmaceuticals LLC in ruling that the patent covering the drug s thrice-wee.

Novartis AG s decision to fold a unit that was working on a novel cancer therapy casts doubt on other companies that are betting on what s seen as one of the most exciting approaches to fighting the disease. In a surprise move Wednesday, the Swiss drugmaking giant, a champion of the experimental therapy known as CAR-T, said research related to it would no longer be housed in a separate div.

WILLOUGHBY, Ohio, Sept. 1, 2016 /PRNewswire/ — Alpha Imaging, distributor of medical imaging equipment headquartered in Willoughby has been recognized by Inc. magazine as one of the 5000 fastest growing companies in the US for the 9th consecutive year. The Inc. 5000 is ranked according to percentage revenue growth over a three-year period. To qualify, companies must have been founded a.

RACINE, Wis. Sept. 1, 2016 /PRNewswire/ — SC Johnson today announced that it has completed an acquisition with STERIS for its Applied Infection Control (AIC) business. STERIS is a leading provider of infection prevention and surgical procedural products and services, focused primarily on healthcare, pharmaceutical and research and medical device companies. This acquisition adds a full ran.

Pfizer s $14 billion deal for Medivation has begun shaking up immuno-oncology (I/O), and the ripple effects are affecting at least one other cancer immunotherapy developer. Pfizer has sought to justify the deal as a faster path to the oncology leadership that until now the pharma giant has only shown in flashes, such as with its successful breast cancer therapy Ibrance (palbociclib).

Suffolk County accused several companies, including Purdue Pharma, Johnson Johnson, and Endo of using deceptive marketing to downplay the risks of their painkillers.

Edison Investment Research – Pharmaceutical & healthcare – Nexstim: Nexstim shareholders have agreed to the 12m funding package announced in July so management has cash until into early 2018. Cost savings of 2.3m per year have been initiated with cuts of 1.6m in the US as a distributor sales model is implemented. This gives lower margins but offers a flexible cost base. The st.

Los Angeles Pharmaceutical Industry – Dutch, French Canadian Interpreting #top #drug #manufacturers

#pharmaceutical companies in los angeles


call now

Los Angeles Pharmaceutical Industry

Los Angeles Pharmaceutical Companies Need Language Services in French, French Canadian and Dutch

Pharmaceutical companies who market countries around the world need to translate various forms of information into or from French Canadian, French or Dutch. Translation of manuals, labeling instructions and other collateral material connected with health information or medical devices are a vital element of the products they are selling. It is essential to translate documents that meet cultural differences as well as all United States and international regulations. Aside from linguistic skills, translating medical related content requires specific training and thorough knowledge of the subject matter. There is more to pharmaceutical and medical device packaging and label translation than simply converting one language to another. Text related to pharmacology can be highly technical, sensitive and is always closely regulated. In Los Angeles and around the world it is critical to use language professionals who are certified, credentialed, educated, and experienced linguists. Specific industry expertise ensures that you will consistently receive high quality written and verbal language services. Additionally, using a language company who is ISO 9001 and ISO 13485 certified is of the utmost importance.

Finding Proper Pharmaceutical Manufacturing Translators for Dutch, French Canadian and French is Vital

It is crucial to work with a Los Angeles company that has the expertise and certifications to meet the rigorous standards that apply in medical manufacturing translation. In a field with exacting and specific terminology, pharmaceutical translating of French Canadian, Dutch and French can be complex and difficult. It is of paramount importance to find the most qualified service that can help you meet your objectives. In the area of Pharmaceutical, Bio-tech and Medical translations, Los Angeles sectors such as Non-Profits, bio-engineering, consumer goods, hi-tech manufacturing, bio-medical, medical device manufacturers, medical providers, hospitals and clinics all have a multitude of translating needs.

Who We Work with and Some Examples of AML-Global Projects in Los Angeles, around the country and around the world:

AML-Global works with a who’s who of companies and departments in the public and private sectors. This is a small sampling of who our clients are: Anthem Blue Cross, Cardiac Science Corporation, Cedars-Sinai Hospital, Johnson & Johnson, Kaiser Permanente, St. John’s Hospital, St. Joseph’s Hospital, St. Jude Medical Center, Karl Storz, Staar Surgical, Torrance Memorial, UCLA Medical Center, the University of Rochester Center for Human Experimental Therapeutics, and the University of Southern California Keck School of Medicine. The following list will give you a brief snapshot of the types of projects we have completed: Clinical tests, clinical modules, surveys, benefits announcements, studies, newsletters, web sites, standard operating procedures (SOP’s), directions for use (DFU’s), pharmaceutical engineering guides, ISPE’s certifications, manufacturing practices (CGMP’s), clinical trial documents (IND’s, NDA’s), enhanced documentation, MSDs data sheets, user guides, user manuals, training, quality assurance, compliance, regulatory and quality control sheets.

For a Fast and Free Quote Online, or to submit an order. please click on the service of interest below

What are your communication goals? Every company has specific objectives in mind. Our goal is to ensure that your goals are met. We will work with you in the time frame you require to achieve the success you desire.

AML-Global: Providing Your Pharmaceutical Company with Solutions in Los Angeles

For over a Quarter of a Century, American Language Services (AML-Global) has been a premier provider of language services. We provide top quality services in French, French Canadian and Dutch for a significant number of major corporations in the domestic US market and abroad. We work in Los Angeles and around the world in all languages for written translations, transcriptions and verbal interpreting for pharmaceutical companies, drug and medical device manufacturers. The experienced staff at American Language Services has the experience and cutting edge technology to enable us to find the best qualified local interpreter in every language and location for whatever your assignment may be. American Language Services can be reached 24 hours a day, 7 days a week at 800-951-5020.

Interpretation, translation, transcription, and media specialists offering professional, worldwide multi-language services to every industry.

Click to Upload Files

Featured Clients

Pharma market research #life #cycle #pharma

#pharma market research


La rilevazione delle attività di Non Personal Promotion in Italia, INDAGINE SULLE AZIENDE Nell’ultimo decennio la diffusione di internet ha sì cambiato il modo di vivere delle persone, ma anche le modalità con cui le aziende possono svolgere la propria attività. Per comprendere quanto la diffusione di questo mezzo influenzi le attività di marketing delle aziende Medi-Pragma ha proposto negli

L’ottimizzazione del Media Mix in un’ottica Multicanale La disponibilità dei dati della SOV nella NPP rendono oggi praticabile l’ottimizzazione del Media Mix allargata anche ai canali innovativi, e non solo limitata ai media tradizionalmente adottati per l’informazione scientifica nel farmaceutico e nei medical device. L’approccio metodologico adottato da Medi-Pragma prevede un modello integrato unico, IMPACT, che raccoglie in forma semplice

La rilevazione delle attività di Non Personal Promotion in Italia, INDAGINE SUI MEDICI Nell’ultimo decennio la diffusione di internet ha introdotto nuove modalità di comunicazione che le aziende farmaceutiche stanno iniziando a sfruttare anche per inviare ai Medici le informazioni promozionali. Anche nel settore farmaceutico la comunicazione è sempre più digital e veloce a discapito della tradizionale informazione per mezzo

La rilevazione delle attività di Non Personal Promotion in Italia, introduzione del problema: L’invecchiamento medio della popolazione, la cronicizzazione di molte patologie ad ampia diffusione, la crisi economica e l’ondata di innovazioni terapeutiche ad alto costo hanno condotto le Case a ripensare profondamente le proprie strategie commerciali, ed in particolare a impiegare canali non personali a costo più basso nell’informazione

Who we are

Medi-Pragma was founded in 1984 by Michele Corsaro, who was a successful and renowned Manager in the field of Pharma, working Internationally in the Marketing department of Pfizer and Eli Lilly.Medi-Pragma is still a Family Company in which members ensure the highest Business Knowledge and Quality Standard, representing a tangible asset of the Medi-Pragma services. Being a member of Assirm, EphMRA, ESOMAR and PBIRG, Medi-Pragma is compliant with the highest Quality Standard in conducting market research

Recent Posts

©2016 Medi-pragma | Privacy Policy | Terms & Conditions | Sitemap | Built by Francesco

This website uses cookies to improve your experience. We’ll assume you’re ok with this, but you can opt-out if you wish.Accept Read More

Privacy & Cookies Policy

7 Pharma Stocks and the Prognosis for Profits #leo #pharma #usa

#pharma stocks


7 Pharma Stocks and the Prognosis for Profits

Which pharma stock is the best?

Pharmaceutical firms benefit from a crucial fact of life for consumers. You can always slash the grocery list, stall a new car purchase or shunt that shot of retail therapy. But cutting back on the pills that maintain health and treat chronic conditions? That’s not a wise area, nor a tailor-made one, for trimming the household budget. Yet not all pharma companies deliver that prescribed dose of healthy gains in metered doses: A drug that costs millions to develop can flop during testing phases. Here’s how seven companies stack up in terms of their positions and prospects. When you invest, use as directed, lest portfolio side effects may occur.

Johnson Johnson (ticker: JNJ ): Strike up the Band-Aid.

Johnson Johnson (ticker: JNJ ): Strike up the Band-Aid.

(Neilson Barnard/Getty Images for NYCWFF)

JNJ has increased dividends 54 consecutive years and earnings for 32. Since 1986, the stock has skyrocketed from $3.16 per share to about $120. It’s not a spotless investment, though. “Despite a recent fifth consecutive quarter of organic sales growth acceleration, the price-earnings ratio based on consensus estimate for the next four quarters has recently declined,” says Steven N. Violin, senior vice president and portfolio manager at F.L.Putnam Investment Management Co. in Wellesley, Massachusetts. Still, “that level is roughly in line with the S P 500.”

Acadia Pharmaceuticals (ACAD ): Parkinson’s promise.

Acadia Pharmaceuticals (ACAD ): Parkinson’s promise.

Acadia is sitting on a potential billion-dollar breakthrough. Nuplazid, a drug approved for Parkinson’s disease psychosis in April. “It is also in phase two of testing for Alzheimer’s and schizophrenia,” says K C Ma, director of the George Investments Institute at Stetson University in DeLand, Florida. Despite negative earnings. “Acadia has a textbook profile for a pharmaceutical takeover target,” he says. “It is rumored that Biogen (BIIB ) is eyeing them.”

Pfizer (PFE ): Blood thinner winner.

Pfizer (PFE ): Blood thinner winner.


One thing worse than Viagra wearing off is your Viagra patent wearing off. Pfizer has lost protections on that drug and other cash cows, including Celebrex, Zyvox, Lyrica and Lipitor. But newer products have picked up the slack. “Breast cancer drug Ibrance is off to a great start after launching in early 2015, logging more than $500 million in sales last quarter,” says James Brumley, analyst and feature writer at “Blood thinner Eliquis has made strong showings recently as well.” Meanwhile, Pfizer has 17 drugs in late testing stages.

Portola Pharmaceuticals (PTLA ): Pfizer’s blood brother?

Portola Pharmaceuticals (PTLA ): Pfizer’s blood brother?

This year hasn’t been kind to Portola stock, off 60 percent in 2016 and trading at $20 per share. But AndexXa, a reverse anti-coagulant to stop bleeding for those on blood thinners, could stanch the hemorrhage. The drug is in final tests. “More than 100,000 patients in the U.S. need it and it’s the only one of its kind,” Ma says. If it succeeds, AndexXa would pair ideally with Pfizer’s anti-coagulant Eliquis – and could presage a major move. “The Street speculates Portola could be Pfizer’s next takeover target.”

Eli Lilly and Co. (LLY ): All in on Alzheimer’s drug.

Eli Lilly and Co. (LLY ): All in on Alzheimer’s drug.

If you bought Eli Lilly stock a year ago, you’re within pennies of where you are today, with share prices shy of $80. There have been some marked bounces along the way – as high as $90, as low as $69 – but those in the buy-and-hold crowd now grasp some solid gains. LLY has more than doubled over the last five years and expect explosive earnings if solanezumab, the drug Lilly is developing to halt the course of Alzheimer’s, emerges from its current trials as a success.

Eagle Pharmaceuticals (EGRX ): Patented profits.

Eagle Pharmaceuticals (EGRX ): Patented profits.

Last year, Eagle’s share price quadrupled to $89 following a blockbuster licensing deal with Teva Pharmaceuticals (TEVA ). Though EGRX has dropped a third this year, share prices spiked 28 percent June 9 after Treanda, a Teva drug used to treat leukemia and lymphoma, won patent protection through 2026. Eagle makes Bendeka, a fast-acting version of Teva’s drug and a follow up to bendamustine, the first leukemia-lymphoma medication Teva licensed. Eagle also hopes to win FDA approval this year on Kangio, a blood thinner that also promises to attract licensing interest.

Bristol-Myers Squibb Co. (BMY ): Opdivo dive bomb.

Bristol-Myers Squibb Co. (BMY ): Opdivo dive bomb.

That thud you heard a few weeks back was BMY stock losing 20 percent of its value in just two days, following news that its drug Opdivo flunked trials for treating advanced non-small cell lung cancer. “The company and its stock are in trouble,” says Jeffrey Zucker, president of Green Lion Partners. “While many investors feel the company’s stock is showing signs of a reversal, I’d venture to say that it’s too soon to buy in, especially after having taken such a beating.”

See More:

Pharma Equipment #mankind #pharma

#used pharma equipment


Pharma Equipment

Our latest machines

About us

Pharma Equipment trades extensively throughout the world, both buying and selling used processing and packaging machinery for the Pharmaceutical, Chemical and Cosmetic industries.

Our customer base spans across the globe ranges from large multinationals to small start-ups looking for their first machinery.
We sell all types of production and packaging machinery from individual machines, complete lines to complete departments. We are also able to offer our services in disposing of assets from complete factories.

We offer machines either from stock or as brokers where the machines are offered directly from our customers’ factories.

Pharmacy and Pharmaceutical Information on the Internet #pharmaceutical #contract #manufacturing

#pharmaceutical information


PharmWeb was launched in 1994 as an online community of pharmacy, pharmaceutical and healthcare-related professionals with over 40,000 self-registered users (probably significantly higher as we stopped monitoring in the 90s). PharmWeb was the first pharmaceutical portal and one of the oldest web sites on the Internet when it closed in August 2016.

PharmWeb was a fantastic achievement and a great deal of fun, particularly in the pioneering wild west days of the early 1990s when the Internet was in its infancy. In 2000 we were the subject of a �20 million buyout!

PharmWeb was only possible with the support of many colleagues, friends and of course the support of my long suffering partner Felicity. I recall in the early days when many colleagues dismissed the (phenomenon that was the) Internet as a flash in the pan! We were not deterred and predicted the information revolution that has come to pass, and indeed many of the services launched on PharmWeb were pioneering at the time. Much of the early services were the result of the programming skills of the team behind PharmWeb as many of today’s off the shelf packages were just a twinkle in a developer’s eye.

Whilst there are too many people to thank individually, I would like to particularly acknowledge a few people who were part of the PharmWeb journey:

John Heaton
John passed away in 2010. John was a friend and drinking partner and introduced me to the Internet in the early 1990s with the launch of Mosaic. Development of PharmWeb would not have been possible without John’s knowledge of Unix, programming skills and enthusiasm. He is missed by all those who knew him.

Anthony Howarth
Tony was an undergraduate and postgraduate student when I was at the University of Manchester. Tony had a passion for technology and whilst much of the software ran off a Unix box, many of the databases and online forms were delivered from a Mac server and Tony was responsible for much of the development work. I have lost touch with Tony, but if you read this, the Apple PowerMac G4 (450MHz) server (running Mac OS 9.0.4) we set up in November 1999 was still in operation until the site closed in 2016!

Rich Ferrie
Commercialisation within an academic environment has its moments, Rich helped me to maintain my sanity in some of the more interesting moments.

Mirror Site Hosts
Many people reading this may not recall the Internet of the 1990s where connectivity across the continents was often patchy. Colleagues across the globe hosted PharmWeb mirror sites, and it was a pleasure to meet some of them in person during my travels.

  • Gail Higgins at The School of Pharmacy and Pharmaceutical Sciences, Faculty of Science, University of Sydney, Sydney, Australia.
  • Newton Pereira at the Department of Pharmacy, University of S o Paulo, Ribeir o Preto, Brazil.
  • Terry Moorby at Industry Canada, Canada.
  • Laszlo L Tornoci and Janos Glanz at Pro Patiente – Health and Medicine, Budapest, Hungary.
  • Kenji Ishikawa and Michiko Yamamoto at The National Institute of Health Sciences, Tokyo, Japan.
  • Elize van Dijken and Banie Boneschans at the Potchefstroom University for Christian Higher Education, Potchefstroom, South Africa.
  • Charles Rezac at The University of Kansas Medical Center, Kansas City, KS, USA.
  • Steve Saklad at The College of Pharmacy, University of Texas, San Antonio, TX, USA.
  • Iosif Vaisman at The School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

You can follow the development of the site on the Wayback Machine.

I hope you enjoyed using PharmWeb, au revoir!

Some early publications.

D’Emanuele, A.,
The Internet: (1) A guide to the information superhighway.
Pharm. J. 254, 29-31, 1995.

D’Emanuele, A.,
The Internet: (2) Connecting and searching for information.
Pharm. J. 254, 58-59, 1995.

D’Emanuele, A.,
The Internet: A global communication tool.
Int. Pharm. J. 9, 68-72, 1995.

D’Emanuele, A.
Internet no panacea – but it’s getting there.
Information World Review, 108, 22-23, 1995.

D’Emanuele, A.
The Internet – hype or panacea.
Community Pharmacy, March 1996, 16-17, 1996.

D’Emanuele, A.,
The Communications Revolution.
Int. Pharm. J. 10, 129-134, 1996.

D’Emanuele, A.
The Internet – dream or virtual reality?
Community Pharmacy, March 1997, 33-36, 1997.

D’Emanuele, A.
PharmWeb – pharmaceutical information on the Internet.
Health Information Management: What Strategies.
S. Bakker (ed), Kluwer Academic Publishers, Dordrecht, The Netherlands, 219-223, 1997.

D’Emanuele, A.
The Internet and PharmWeb.
Emerging Themes and Technologies in Pharmacy Education
P. Bourlioux, A. A. Hincal, S. Senel, A. T. Florence (Eds), Safak Press, Turkey, 97-100, 1997.

D’Emanuele, A.,
The Internet.
Pharm. J. 260, 26-28, 1998.

D’Emanuele, A.,
The Internet: A tool for delivering and exchanging information.
Int. Pharm. J. 10, 129-134, 1998

D’Emanuele, A.,
PharmWeb – pharmaceutical information on the Internet.
Pharmaceutical Science and Technology Today, 1, 2-4, 1998

D’Emanuele, A.,
An Internet primer: What does the pharmacist need to know?
Int. Pharm. J. 14, 7-10, 2000.

PharmWeb – Copyright . All rights reserved.

The final home page.

Full programs of major pharmacy, pharmaceutical and health-related conferences around the world plus the PharmWeb Conference Calendar.

PharmWeb Discussion Forum
The PharmWeb Discussion Forum is a collection of discussion groups and mailing lists specialising in specific aspects of medicine, pharmacy, pharmaceutical sciences and health-related issues. The discussion groups and mailing lists are designed to focus on specific areas and are moderated to ensure that discussions are within the scope of a particular discussion group.

World Wide Pharmacy Colleges/Departments/Schools
This is a comprehensive database of world wide pharmacy schools. The schools list is in the form of a searchable database and is regularly updated. The database includes contact names, addresses, telephone and FAX numbers, and Internet addresses where available.

Government and Regulatory Bodies
Links to government and regulatory bodies around the world.

Patient Information
Find helpful advice on a range of conditions and diseases online.

PharmWeb Yellow Web Pages
Your directory to pharmaceutical information on the Internet. Includes companies, pharmacies, hospitals, plus much more. Each site is evaluated by our team of researchers before addition to the directory.

A directory of pharmaceutical and health-related societies around the world. Also included is a list of International Pharmaceutical Federation (FIP) member organisations (including addresses, telephone and FAX numbers).

PharmWeb Appointments
Job vacancies in science and the health professions, updated regularly. If you want to be the first to know about a new vacancy why not join the PharmWeb Appointments Alert?

PharmWeb Virtual Library
A repository of pharmaceutical information for educational and research purposes.

Links to various science and health-related newsgroups.

Continuing/Further Education
Links to pharmaceutical and health-related courses and teaching information.

Special Interest Pages
A resource of links to sites specialising in science, drugs and health-related subjects. A starting point for information other than pharmacy.

PharmWeb Index
An A to Z index of information held on PharmWeb.

History of PharmWeb
PharmWeb was the first hierarchical information resource on the Internet for pharmaceutical and health-related information. How did it all start?

Pharmacy and the Internet
This page contains information on pharmaceutical publications related to the Internet and considers the applications of the Internet to pharmacy and new online pharmacy services.

PharmWeb Internet Directory
Links to some of the best sites on the Internet including search engines, news, weather, entertainment, and many other interesting sites.

What’s New on PharmWeb?
Find out about the latest developments on PharmWeb.

Access Statistics
How many people use PharmWeb? Detailed access statistics for the main PharmWeb servers.

How to Add/Edit Links
Do you want to add or edit any link on PharmWeb, this tells you how to do it.

PharmWeb and its Services
What can PharmWeb do for you? A summary of the services that PharmWeb provides.

Problem Solver
Some of the common problems encountered using web browsers.

Comments and Suggestions
Let us know what you think of PharmWeb. Many developments have been the result of user feedback.

Organisations on PharmWeb
PharmWeb is here as a result of the support of major pharmaceutical and health-related organisations.

Contact PharmWeb
This page contains information on your PharmWeb contact.

Pharmaceutical Market Research Company #hetero #pharma

#pharma market research


Market Research

The global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within three years. The 10 largest drugs companies control over one-third of this market, and it is predicted that North and South America, Europe and Japan will continue to account for a full 85% of the global pharmaceuticals market well into the 21st century. (Source: WHO)

Many pharmaceutical companies currently spend almost twice as much on marketing their products as they do on research and development, with smaller pharmaceutical companies struggling to stand out against the giant global competitors.

Please get in touch with Kate Slater, Associate Director if you are interested in understanding how we can help you. Some examples of how we help include:

  • How can we help you to understand the patients needs and the journey they have travelled through diagnosis? We have experience of conducting research with patients suffering from a wide range of conditions using both qualitative and quantitative research.
  • How can we help you to develop messages that will stand out in the sales process? We conduct qualitative and quantitative research at all stages in the product development process to understand the most appropriate messages for marketing?
  • How do you tackle the challenge of providing enough information to a practitioner to generate sales without overloading with too much information? We conduct qualitative detail aid testing with both GPs and Specialists to understand how to present large amounts of detailed information in the most appropriate format.
  • How do you tackle the needs of a complex pharmaceutical market with a retail oriented strategy of over the counter products? We combine the experience of our healthcare team with the FMCG and Retail teams to co-manage both qualitative and quantitative research that can answer consumer market questions within the complexities and regulations of the pharmaceutical industry.

DJS Research is a mid-sized family owned full service research agency with comprehensive research resources including an international telephone interviewing unit. Pharmaceutical research is led by Kate Slater, Associate Director who has more than 10 years experience in this sector. Our services include:

  • Desk research
  • Quantitative interviewing (e.g. online surveys or telephone interviewing)
  • Qualitative interviewing (e.g. depth interviews, group discussions and ethnographic studies)

We are Certified by the British Healthcare Business Intelligence Association. Our interviewers and staff are trained to BHBIA standards and we abide by the regulations laid down by them for market research in the pharmaceutical sector.

Some of the clients DJS Research have worked for in the pharmaceuticals sector include:

Advanced Search

Generic pharmaceuticals #pharmaceutical #company #news

#generic pharmaceutical


Generic pharmaceuticals

What are generic pharmaceuticals?

Generic medicines are the equivalent of originator medicines whose patent protection has either expired or of those that never had one. Generic medicines contain the same active pharmaceutical ingredients as the original pharmaceuticals. Generic pharmaceuticals are also equivalent to the originator medicines in terms of quality, efficacy and safety. This has been confirmed by therapeutic practice, market authorisation documentation and bioequivalence research. Generic pharmaceuticals are also increasing in importance around the world because they offer the same quality and are an acceptable alternative form of treatment compared to originator medicines.

Krka generics offer added value

In terms of strategy, Krka is primarily a generic pharmaceutical company. We develop and market generic products with added value, i.e. high quality products at accessible prices that have made Krka a recognisable name in many parts of the world.
Our generic pharmaceuticals are based on our own innovative procedures for synthesising or isolating active pharmaceutical ingredients and our own innovative pharmaceutical formulations. Today, we have over 350 patent protected innovations for which numerous patents have been issued in various European, American and Asian countries.

Quality, efficacy and safety

API quality is verified via extensive laboratory testing using the most sensitive, reliable and validated analytic methods and devices. Given the improvements in synthesis and evaluation processes, generic APIs can be of an even higher quality that the API of the original producer.

The Certificate of Suitability (CoS) issued by the European Directorate for the Quality of Medicines (EDQM) is the highest quality standard in Europe. It confirms that an API meets European pharmaceutical standards. Krka has obtained this certificate for a number of APIs.

A Krka generic pharmaceutical is equivalent to the originator products. Pharmaceutical equivalence is confirmed by in vitro release tests, and therapeutic equivalence throughin vivo testing and bioequivalence research. In both cases Krka pharmaceuticals are directly compared to those of an original pharmaceutical producer.

The efficacy and safety of Krka products is also regularly verified and confirmed in practice. Extensive clinical trials form part of the pre-registration (phase III) as well as the post-registration research process (phase IV) and pharmoequivalence work.

Krka, d. d. Novo mesto

Health News – Medical News Today #action #pharma

#healthcare news


Medical News Today
Your source for health news since 2003.

  • Caffeine may complicate blood pressure treatment and diagnosisCaffeine has been linked to increases in blood pressure, and a new study suggests that it may interfere with blood pressure testing and treatment. Hypertension
  • Heatwaves, cold snaps may raise preterm birth riskExposure to extreme heat or cold during pregnancy may increase the risk of preterm birth, say researchers from the National Institutes of Health. Pregnancy / Obstetrics
  • Crohn’s disease: Potential treatment to prevent fibrosis uncoveredScientists have made a significant discovery in understanding the cause of fibrosis in Crohn’s disease, which offers a target for potential therapies.
  • Height and spatial awareness: who draws the short straw?Comparing short and tall people has been a scientific pastime for many years. The latest difference to be unearthed appears to be spatial awareness. POPULAR
  • Antibiotics in early life could raise children’s food allergy riskChildren prescribed antibiotics in the first year of life may be at higher risk of food allergies, with the risk increasing with higher antibiotic use.
  • Reefer slackness: Does marijuana reduce motivation?Does popular belief that cannabis reduces motivation hold true? Researchers investigate across two studies, yielding surprising findings.
  • Sepsis deaths fell dramatically after hospital implemented simple stepsHospital cuts sepsis deaths by 40 percent after introducing relatively simple steps such as increased ward nurse training and a special observation chart.
  • Brain maintains representation of hands decades after amputationThe University of Oxford have found that the brains of people who have had their hands amputated remember the missing body parts decades after amputation.
  • Simple computer model sheds light on sleeping brainThe sleeping brain still holds many secrets. A new, simple modeling technique promises to help uncover mechanisms at work during memory consolidation.
  • What is the Function of the Hypothalamus?The hypothalamus is a small area in the center of the brain. Learn about its different roles and the disorders that can affect it.
  • Marijuana use rising as more people think it is safeThe number of Americans who perceive marijuana as a risky drug fell between 2002-2014, fueling an increase in use, find researchers.
  • Childbirth pain linked to risk of postpartum depressionWomen who experience pain for longer than 4 weeks after childbirth may be more likely to develop postpartum depression, a new study suggests.
  • WHO revise STD treatment guidelines as threat of antibiotic resistance escalatesPrompted by rapidly increasing resistance to antibiotics, the WHO have revised treatment guidelines for three STDs: gonorrhea, syphilis, and chlamydia.
  • Sexual problems more common among young women after heart attackYounger women between ages 18-55 years are more likely than men to experience sexual function problems in the year following a heart attack, study finds.
  • How much influence does alcohol have on female fertility?Although most doctors recommend cutting out alcohol when trying to become pregnant, the exact relationship between fertility and alcohol is not understood.
  • All You Need to Know About the Glucose Tolerance TestA simple blood test can often detect diabetes. If the test produces borderline results, a glucose tolerance test may help with the final diagnosis.

    Other medical and health news

    Making memories stronger and more precise during aging

  • Rotten egg gas could help protect diabetics from heart complications

  • Los Angeles California Pharmaceutical Jobs #dishman #pharma

    #pharmaceutical companies in los angeles


    Los Angeles, California Pharmaceutical Jobs

    Looking for Pharmaceutical Jobs in Los Angeles, California. See currently available Pharmaceutical job openings in Los Angeles, California on Browse the current listings and fill out job applications. is the starting point for a job search in any pharmaceutical job in Los Angeles, California. We provide job resources for Pharmaceutical positions throughout the industry in Los Angeles, California. also provides Pharmaceutical jobs listings from around the United States. Job seekers can search and apply for jobs in Pharmaceutical by either city or state. is a pharmaceutical job search resource for job seekers in Los Angeles, California. Here you can easily find all Pharmaceutical jobs in Los Angeles, California, post a resume, and research your career.

    Get started on your pharmaceutical job search in Los Angeles, California on today.

    Current Los Angeles, California Pharmaceutical Jobs

    Showing 1 to 20 of 248 jobs

    CA – Los Angeles

    Territory Sales Representative – Pharmaceutical Sales About Sebela Pharmaceuticals: Sebela Pharmaceuticals is a rapidly growing company located in.

    CA – Santa Clarita

    Territory Sales Representative – Pharmaceutical Sales About Sebela Pharmaceuticals: Sebela Pharmaceuticals is a rapidly growing company located in.

    CA – Los Angeles

    Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Through ongoing expansi.

    CA – Los Angeles

    Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Through ongoing expansi.

    Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Through ongoing expansi.

    Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Through ongoing expansi.

    Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Through ongoing expansi.

    Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Through ongoing expansi.

    CA – Los Angeles

    Pharmaceutical Sales Representative – Neurology PDI at Publicishealth as a great opportunity for pharmaceutical sales representatives in the neurol.

    Pharmaceutical Consultant Pharmacy Pharmaceutical Consultant Pharmaceutical Consultant Firm #forrest #pharma

    #pharma consultant


    Maximize the effectiveness of your sales force?

    Coach product management?

    Slow the erosion of patent expired products?

    Reduce the cost of company meetings?

    Position your products for the highest rates of return?

    Establish a co-promotion arrangement?

    Find hidden revenue opportunities?

    Confirm what your product positioning strategy is?

    Create marketing programs that have documented

    We are a small boutique-consulting firm with access to a variety of experts in the industry. We can offer your organization a wealth of experience and knowledge for a fraction of the cost of the major consulting firms.

    In today’s highly complex pharmaceutical business environment, it is imperative to maximize product promotional returns with the limited resources available.

    Pharma Consultants has a broad range of experience and expertise in a number of areas:

    Slowing the erosion of patent expired products

    Contract product marketing

    Product Market Strategies and Promotion

    If your organization has a need in any of these areas please call me for a free consultation.

    Why spend more when you can get more for less?

    New pharmaceuticals #pharmaceutical #jobs

    #new pharmaceuticals


    Athenex Announces the Addition of James Hussey to Lead its Commercial Business Activities

    Athenex announced today that James Hussey has joined the Company as Executive Vice President of Athenex Pharmaceutical Division. In this capacity, Mr. Hussey will be responsible for the execution of the commercial aspects of this business unit including strategy, new products, manufacturing, distribution, sales and marketing.

    Governor Cuomo Announces Major Expansion of Athenex Creating 1,400 Jobs in Western New York

    Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years.

    State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.

    Governor Andrew M. Cuomo recently announced a major expansion of Athenex that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 square foot manufacturing facility in Dunkirk.

    Rendering of new 300,000 square foot facility

    Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

    Athenex recently announced the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.

    Athenex is a privately held company with offices in both China and the US. Our mission is to improve the lives of cancer patients throughout the world, through the discovery, development and commercialization of innovative oncology products and therapeutic solutions.

    North American Headquarters
    Conventus Building
    1001 Main Street
    Suite 600
    Buffalo, New York 14203

    Asia Headquarters
    Unit 608-613, IC Development Centre,
    No. 6 Science Park West Avenue,
    Hong Kong Science Park, Sha Tin, New Territories, Hong Kong

    P: (852) 2607.4100
    F: (852) 3996.7454

    Other Athenex Companies

    Services for Pharmaceutical products, Analytical Methods, Ecotoxicological studies, Environmental fate and behaviour studies #pharmacia

    #pharmaceutical products



    A Medicinal product is defined as any substance or combination of substances presented for treating or preventing disease in human beings. Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product.

    Medicinal products are regulated by the Directive 2001/83/EC. According to the implementation of this Directive the evaluation of the potential environmental risks posed by medicinal products should be submitted, their environmental impact should be assessed and, on a case-by-case basis, specific arrangements to limit the impact should be considered.

    BioTecnologie B.T. Tests List

    Physical, chemical and technical properties

    • Content of the Active Substance
    • Content of the Relevant Impurities

    • Fully Equipped Analytical Laboratory (HPLC DAD, GC/MS, LC MS/MS. etc.)
    • Method set-up and Validation
    • Residue analysis, Certificates of Analysis

    Toxicity to Aquatic organisms

    • Daphnia magna Growth and Reproduction test (OECD 211 )
    • Growth Inhibition test on Freshwater Alga and Cyanobacteria (OECD 201)
    • Biodegradation – Activated Sludge Respiration Inhibition (OECD 209)

    Toxicity to Terrestrial organisms

    • Soil Micro-organisms, Nitrogen Transformation test (OECD 216)
    • Earthworms, Acute Toxicity test (OECD 207)
    • Springtails, Collembolan Reproduction test in Soil (OECD 232)
    • Terrestrial Plant test, Seedling Emergence and Seedling Growth test (OECD 208)

    Environmental fate and behaviour studies

    • Ready Biodegradability (OECD 301)
    • Adsorption-Desorption Using Batch Equilibrium Method (OECD 106)
    • Estimation of the Adsorption Coefficient on Soil and on Sewage Sludge Using HPLC (OECD 121)
    • Aerobic and Anaerobic Transformation in Aquatic Sediment System (OECD 308)
    • Aerobic and Anaerobic Transformation in Soil (OECD 307)

    Pharmaceutical Products Portfolio #lupin #pharma

    #pharmaceutical products




    A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. We offer high quality, affordable generic medications that help reduce healthcare costs around the world.

    Alvogen also sells and markets a growing portfolio of OTC (over-the-counter) medicines and medical devices. In November 2013, the company announced that it would invest over $500 million in the development of biopharmaceuticals through its sister company, Alvotech.

    Marketed products
    Generic development projects

    Fast growing portfolio

    Alvogen operates three regional hubs with manufacturing and R D capabilities in the U.S. South Korea and Romania. Alvogen’s lines of business include: product development, contract manufacturing and research (CMO), and sales of generic and brand medicines, biosimilars and OTC s.


    Our goal is to ensure that the benefits and risks of a medication are continuously monitored and well-understood by regulators, healthcare providers and patients. Alvogen maintains a pharmacovigilance system, collecting information throughout the lifecycle of each product.


    Alvogen has commercial operations in more than 30 countries, with regional hubs, manufacturing and R D capabilities in the U.S. South Korea and Romania.

    Alvogen has 350 generic products on the market, with over 200 strategically selected development projects in the pipeline. Connect with local teams to learn more about product offering in your region.

    Glenmark Pharma Debuts in US with NC Plant #7tm #pharma

    #pharmaceutical companies in charlotte nc


    Glenmark Pharma Debuts in US with NC Plant

    One of Glenmark’s pharmaceutical manufacturing lines.
    –Photos courtesy of Glenmark Pharmaceuticals Ltd.

    An India-based global pharmaceutical company has chosen North Carolina for its first North American manufacturing facility.

    Glenmark Pharmaceuticals Ltd. has purchased a 15-acre site in the Union County city of Monroe, near Charlotte, for the facility. The company plans to spend some $18 million to set up its drug manufacturing plant in an existing 102,000-square-foot building in the Monroe Corporate Center near the Charlotte-Monroe Executive Airport.

    Glenmark, headquartered in Mumbai, said it expects to employ 41 people by the time it begins production of oral solid dermatology, hormone replacement and cancer drugs at the Monroe plant in 2015. During the subsequent five years the company plans to add injectable and topical formulations to its production line.

    “Our plan to set up a new state-of-the-art manufacturing facility in the U.S. underlines the fast-paced growth the company has witnessed in a short span of eight years in the U.S. market, and our long-term commitment to the country,” said Glenn Saldanha, chairman and managing director.

    Glenn Saldanha, Glenmark chairman and
    managing director

    “The U.S. is a key strategic market for Glenmark and it is important for us to have a manufacturing base here to serve our growing business in the country.”

    Glenmark, best known in the U.S. for its generic drugs, has 14 plants in four countries — India, Brazil, Argentina and the Czech Republic.

    The publicly traded company was founded by Glenn Saldanha’s father Gracias, who died in 2012.

    Glenn has a bachelor’s degree in pharmacy from Mumbai University and an MBA from New York University’s Leonard Stern School of Business. Before joining Glenmark, Saldanha worked in the United States for Eli Lilly and PricewaterhouseCoopers.

    In 2013, Forbes listed the now 44-year-old Saldanha as India’s 57th richest person, with a net worth of $1.2 billion.

    About the Author »

    The Effort to Rid TV of Pharma Ads #pharmaceutical #drugs

    #pharma advertising


    Source: Benjamin Stone/Flickr

    The average American TV viewer can expect to watch up to 30 hours of prescription drug advertising each year, the editors of Scientific American noted recently, with drug makers spending $5.2 billion on such ads in 2015. That’s a 60 percent increase on the total spent four years earlier, with no signs of slowing down.

    Ever since the FDA in 1997 relaxed its rules on pharmaceutical advertising, allowing drug makers to bypass healthcare providers and market directly to American patients and consumers, the amount spent on TV advertising in particular has risen incrementally by hundreds of millions of dollars each year, driving up medical costs that are then passed on to those patients and consumers, creating a climate rife with overdiagnosis and overmedication. The United States and New Zealand are the only advanced economies on the planet to allow such advertising.

    Source: Food and Drug Law Journal, 2002

    There are clear signs, however, that doctors and the American public have reached a breaking point over the ads. Last November, the American Medical Association called for an outright ban on them, a position supported by the World Health Organization and other health agencies. Voicing concern about “the role that marketing costs play in fueling escalating drug prices,” AMA Board Chair-elect Dr. Patrice Harris noted at the time that “direct-to-consumer advertising inflates demand for new and more expensive drugs. even when these drugs may not be appropriate.”

    A new STAT-Harvard poll indicates that the AMA’s position has clear majority support from the American public. According to the poll, 57 percent of Americans favored removing pharma ads from TV; 39 percent were opposed. 44 percent of those polled also said the FDA should be allowed not to approve a new drug if it considers the price too high.

    Sentiment is one thing; making such initiatives legally binding is another. Following the AMA proposal, reaction from PhRMA, the organization representing the drug companies, was swift and fierce, signaling that the law violates First Amendment protections for commercial speech and would face legal challenges whose costs would once more be passed on to American patients.

    But as the editors of Scientific American note in their editorial. moves short of an outright ban may be more effective. The industry’s ad-based tax deduction could be eliminated, a position advocated by Hillary Clinton. The FDA could also decide to hold drug makers to their claim that such advertising is an educational tool, a position requiring more-stringent standards than are currently enforced.

    “Another constructive move,” they note, “would be for Congress to pass the Responsibility in Drug Advertising Act, introduced in February by Representative Rosa DeLauro of Connecticut. The bill would require a three-year moratorium on ads for new prescription drugs approved by the FDA.”

    With prescription drug prices rising in tandem with pharma advertising, the status quo is clearly unsustainable and needs root-and-branch reform. “Many of the newest ads,” note the editors at Scientific American, “are for premium drugs for life-threatening diseases or rare conditions that can cost tens of thousands of dollars and require large, out-of-pocket patient co-payments. After seeing an ad, patients may press physicians for a prescription without understanding the complex criteria needed to determine eligibility for treatment.”

    And press their doctor they do, in ways groups such as PhRMA are obviously keen to maintain. Last October, a Kaiser Family Foundation survey found that 28 percent of people who viewed a drug ad subsequently asked a physician about the medicine and that 12 percent walked out with a prescription.

    Submitted by Anonymous on May 15, 2016 – 10:59am

    I like the pharmaceutical ads. They are pretty and colorful. Most of them show people who simply take a pill and suddenly become active hikers, experts in photography, the build pottery sheds, they play the violin, they are happy farmers, active basketball players and have fabulous romantic relationships. Those that take antidepressants suddenly have wonder family relationships or, at least, arent’ crying. And don’t get me started about the lucky men who take Viagra, they are all good looking and their women have a voracious sexual appetite.

    I would never ask my doctor about any of these crazy pills. However, I have to respect these pharmaceutical companies. They’ve performed excellent advertising research. The pharmaceutical companies, and the fast food companies, are the only ones that show single people being happy and enjoying their lives. It’s a pleasant change from most other advertisers that are still stuck in family-mode.

    I’d rather watch a pharmaceutical commercial than a car commercial any day.

    Submitted by Christopher Lane Ph.D. on May 15, 2016 – 11:12am

    Your position is strikingly similar to that of a famous New Yorker cartoon from 2001–one I can’t reproduce here, but it features a woman saying to her doctor: “I think the dosage needs adjusting. I’m not nearly as happy as the people in the ads.”

    Let me add a related caution by the editors of Scientific American: “An ad that conflates an aura of glowing health and the prospect of an amorous liaison with a list of dire cardiovascular symptoms [legally required mention of an abundance of side effects] is a paradigm of confused messaging because it does not provide the viewer with a clear guide to weighing both benefits and costs entailed in using a prescription medicine.”

    Post Comment

    Generic pharmaceuticals and competition #pharmaceuticals #jobs

    #generic pharmaceutical



    Generic pharmaceuticals and competition

    Entry by generic pharmaceuticals can enhance competition in the drug market by offering more choice and by lowering drug prices to the benefit of health customers. At the same time, innovation in the pharmaceutical sector should be sustained, notably by allowing innovators to obtain intellectual property rights on their originator drug.

    Competition concerns arise, however, when originator companies use their intellectual property rights to delay or to prevent generic entry. Some pharmaceutical companies are using new potentially anticompetitive strategies.

    In June 2014 meeting, the OECD Competition Committee addressed recent developments regarding such strategies, building on earlier discussions (see 2009 Roundtable Proceedings as well as the 2014 Global Forum discussion ). Participants have also looked at how competition law enforcement can contribute to enhancing effective competition in the pharmaceutical sector. An extract of the main findings from the discussion is below.

    Key findings from the discussion

    Top pharmaceutical companies #ironwood #pharma

    #top 50 pharmaceutical companies


    Top pharmaceutical companies

    The top pharmaceutical companies 2016, or big pharma (bigpharma)/top pharmaceutical/pharma 50 companies, as commonly used in the industry, are responsible for a large proportion of the revenue generated by the pharmaceutical industry. The top pharmaceutical companies were responsible for revenues of $692 billion in 2015.

    Derived from Current Agreements. CP Insight Top Pharmaceutical Companies (Bigpharma 50) provides details of the top life science companies worldwide.

    The top pharmaceutical companies are also responsible for a significant number of partnering deals and alliances every year.

    A comprehensive listing of the top pharmaceutical companies / Bigpharma 50 of 2016, by 2015 revenues is provided below.

    Searching for more deal information? Current Partnering offers the following options:

    • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing. co-promotion to distribution, biomarkers to drug delivery. oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
    • Current Agreements | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

    Tag Cloud

    2016 Wildwood Ventures Ltd.

    Medical and Pharma Website Design Templates #cafe #pharma #boards

    #pharma websites


    Medical and Pharma Website Design Templates

    Pharma Website Templates

    Medical and pharmaceutical companies need to look good on the web. It’s not just for getting customers but also to look good to their vendors and investors. It’s an essential part of the equation for a successful company. The current website might be outdated and it’s probably time to get a new website up in its place.

    These designs can also be used for other type of businesses – not just medical companies.

    These template designs feature stunning design and are available for your business. Images, text and the logo can be changed. Just supply that to us, we’ll get you a proof and then we’ll create your website in a short amount of time.

    Here is an example of a website using a pharmaceutical website design that is modern and responsive:

    If you need a template or theme for your website, please contact Webstix today .

    Website Design
    Professional website design! Manufacturing / Industrial Web Design
    Marketing and Systems Integration Search Engine Optimization
    Get found, increase conversion! Website Maintenance
    Keep your website fresh. Get more traffic!

    Need Website Maintenance?

    Other Pharmacy Events & Webinars – FIP – International Pharmaceutical Federation #cardiome #pharma

    #pharma conference


    International Pharmaceutical Federation (FIP)

    Events and Webinars

    Chronic respiratory diseases (CRD), such as asthma and chronic obstructive pulmonary disease, kill more than four million people every year and affect hundreds of millions more. These diseases erode the health and well-being of the patients and have a negative impact on families and societies, and constitute a serious public health problem in all countries throughout the world. As an international federation of organisations of pharmacists, it is the mission and responsibility of FIP to address issues that broadly affect health and well-being across the globe. Despite the widespread assumption that the problem is one that only affects the developed world, chronic diseases are pandemic. The report by the World Health Organization (WHO), “Preventing Chronic Diseases: a vital investment” provides a background for FIP and its members to become actively involved in educating and advocating for the resolution of this issue. The aim of this series of webinars is to enable pharmacists throughout the world to provide better care for patients suffering from chronic respiratory diseases: (I) Describe the general background for chronic respiratory disorders. (II) Explain the different therapies available. (III) Outline how to help patients make the most of the therapies available, effectively and safely. (IV) Describe different potential services from community pharmacists for CRD patients.

    Chronic respiratory diseases (CRD), such as asthma and chronic obstructive pulmonary disease, kill more than four million people every year and affect hundreds of millions more. These diseases erode the health and well-being of the patients and have a negative impact on families and societies, and constitute a serious public health problem in all countries throughout the world. As an international federation of organisations of pharmacists, it is the mission and responsibility of FIP to address issues that broadly affect health and well-being across the globe. Despite the widespread assumption that the problem is one that only affects the developed world, chronic diseases are pandemic. The report by the World Health Organization (WHO), “Preventing Chronic Diseases: a vital investment” provides a background for FIP and its members to become actively involved in educating and advocating for the resolution of this issue. The aim of this series of webinars is to enable pharmacists throughout the world to provide better care for patients suffering from chronic respiratory diseases: (I) Describe the general background for chronic respiratory disorders. (II) Explain the different therapies available. (III) Outline how to help patients make the most of the therapies available, effectively and safely. (IV) Describe different potential services from community pharmacists for CRD patients. SPEAKER: Nada Hazem Farrag

    The symposium will focus on biologicals and non-biological complex drugs (NBCDs). These complex drugs require a paradigm shift for regulatory approval compared to the requirements for small molecules. These complex drugs are difficult to fully characterize and the tight control of the manufacturing process makes the specific product. The symposium will discuss biologicals and NBCDs, what they are and why are they different, scientific and regulatory advances in bioanalytical methodologies to characterize these biologicals, complex drugs and nanoparticles. SRACD 2016 will present similarities between biologicals and NBCDs. It will focus on potential challenges in therapeutic equivalence evaluation of NBCDs like nanomedicines, iron sucrose complexes, glatiramoids, liposomes and complex ophthalmic emulsions.

    Chronic respiratory diseases (CRD), such as asthma and chronic obstructive pulmonary disease, kill more than four million people every year and affect hundreds of millions more. These diseases erode the health and well-being of the patients and have a negative impact on families and societies, and constitute a serious public health problem in all countries throughout the world. As an international federation of organisations of pharmacists, it is the mission and responsibility of FIP to address issues that broadly affect health and well-being across the globe. Despite the widespread assumption that the problem is one that only affects the developed world, chronic diseases are pandemic. The report by the World Health Organization (WHO), “Preventing Chronic Diseases: a vital investment” provides a background for FIP and its members to become actively involved in educating and advocating for the resolution of this issue. The aim of this series of webinars is to enable pharmacists throughout the world to provide better care for patients suffering from chronic respiratory diseases: (I) Describe the general background for chronic respiratory disorders. (II) Explain the different therapies available. (III) Outline how to help patients make the most of the therapies available, effectively and safely. (IV) Describe different potential services from community pharmacists for CRD. SPEAKER: Fin Mc Caul

    On behalf of the Organising Committee, it gives us great pleasure to invite you to join us at the Australasian Pharmaceutical Science Association (APSA) conference, being held at The University of Sydney from Friday 2nd – Monday 5th December 2016. The APSA Annual Scientific Meetings bring together international and national academics and researchers in the fields of pharmaceutical science, clinical sciences, pharmacy practice, and pharmacy education. The 2016 conference theme is Precision medicine, personalising healthcare, which will cover recent advances and potential for personalised medicine, and encompass symposia on advanced practice, infectious diseases, improving medicines use, drug delivery, big data for precision medicine /e-health and precision therapy. The program will showcase outstanding speakers including the following international and national keynote speakers:

    We work with:

    On this Site:

    Contact Details:

    Pharma Consulting Services #pharmaceutical #manufacturing #jobs

    #pharma consultant


    Pharma Consulting Services

    Scientific and Pharma experts for custom pharmaceutical projects across the life science research cycle

    Nothing should get between you and the market. Tackle challenges and accelerate development with our Professional Services team. Comprised of Pharma R D experts, industry professionals, and business analysts, we understand your challenges. Whether you need a competitive intelligence study fast, or an in-depth scientific research brief, or even a location assessment for a clinical trial program, we can support you and help you meet your objectives faster.

    Contact Pharma Life Sciences Sales

    Call Us

    Please select a region below


    North America

    Outside of North America


    +55 11 8370 9845

    Other Countries

    Europe, Middle East, Africa

    All Countries

    +44 203 684 1797
    +0800 145 6412

    Asia Pacific


    Australia & New Zealand


    +86 10 5760 1200


    +91 11 3044 6419


    Southeast Asia & Pakistan


    +886 2 2503 3034

    Pharma Consulting Services Products:

    Cortellis Opportunity Monitor

    Cortellis Opportunity Monitor automatically watches for industry developments that affect the status of drug licensing candidates you’ve previously considered.

    Life Sciences Professional Services

    Encompasses all of the bespoke projects we offer, from complete one-offs to repeatable capabilities. These services span across all of Life Sciences including science, clinical, business and technology services.

    Thomson Reuters feedback

    Top 10 Pharmaceutical Companies in India #pharma #marketing #research

    #list of pharma companies


    Pharmaceutical Companies in India

    Pharmaceutical Industry in India

    India is the world’s third largest pharmaceutical industry in terms of volume and world’s 13th largest pharmaceutical industry by value. The top 8 to 10 companies including Sun Pharma, Lupin, Dr. Reddy’s Labs and Cipla occupy 70 to 80 percent of the Indian pharmaceutical market space. It is estimated

    by a Fitch Group company named India Rating that the Indian pharmaceutical industry will grow at a rate of 20 percent during 2015-2020. The domestic market is expected to do better this time as the projected growth rate is 10-12 percent during 2015-16 as compared to 9 percent in 2014-15.

    List of Top 10 Pharmaceutical Companies in India

    Here are the top pharmaceutical companies in India in terms of their market capitalisation:

    Sun Pharmaceutical

    Sun Pharma, officially known as Sun Pharmaceutical Industries Limited, was founded in 1983 by Dilip Shanghvi. The company is headquartered in India’s financial capital Mumbai, Maharashtra. Active Pharmaceuticals Ingredients (APIs) and formulations are known to be Sun Pharma’s specialised areas. It targets a wide spectrum of chronic and acute treatments. Its therapeutic segments of over 3000 high quality molecules include psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. On 15 June 2015, Sun Pharma was India’s largest pharmaceutical company with the market capitalisation valued at Rs. 2,01,706.41 crore. Its products and services may be categorised as below:

    • Formulations
    • Active Pharmaceutical Ingredients (APIs)
    • Over-The-Counter (OTC)
    • Antiretrovirals (ARVs)


    Headquartered in Mumbai, Lupin Limited is a multinational pharmaceutical company. An associate professor at BITS-Pilani in Rajasthan, Dr. Desh Bandhu Gupta established Lupin in 1968, which is today one of India’s leading pharmaceutical companies. In Pune, Maharashtra, Lupin has a state-of the-art research and development unit. It is one of the fastest growing companies as far as oncology, cardiology, gastroenterology, central nervous system, anti-infective, anti-asthma and diabetology therapies are concerned. Lupin’s market capitalisation amounted to Rs. 77,115.19 crore on 15 June 2015. Its products and services may be categorised as below:

    • Branded Formulations
    • Advanced Drug Delivery Systems
    • Generics
    • Novel Drug Discovery
    • APIs
    • Biotechnology

    Dr. Reddy’s Labs

    Based in Hyderabad, Telangana, Dr. Reddy’s Laboratories is a multinational pharmaceutical entity. It was founded in 1984 as a manufacturer of APIs. A vast range of pharmaceutical products are offered by Dr. Reddy’s Labs. It has 60 APIs and 190 medications to treat various kinds of ailments. It is now India’s third largest pharmaceutical company in terms of market capitalisation, which was valued at Rs. 56,638.13 crore on 15 June 2015. Its products and services may be categorised as below:

    • Generic Formulations
    • Active Ingredients
    • Pharmaceutical Services
    • Biosimilars
    • Propriety Products


    Dr. K. A. Hamied set up Cipla Limited in 1935, which is one of the biggest biotechnology and pharmaceutical multinational companies of India today. APIs and formulations are produced at 34 state-of the-art Cipla plants spread across the country. Primarily, medicines for treatments of ailments like depression, obesity, cardiovascular diseases, arthritis and diabetes are developed by Cipla. It is India’s fourth largest pharmaceutical company accounting for a market capitalisation worth Rs. 47,025.38 crore on 15 June 2015. Its products and services may be categorised as below:

    • APIs
    • Formulations
    • Veterinary

    Aurobindo Pharma

    Aurobindo Pharma was founded by K. Nityananda Reddy and P.V. Ramaprasad Reddy with others in 1986. Headquartered in Hyderabad, Telangana, Aurobindo Pharma Limited manufactures APIs and generic pharmaceuticals. Six prime therapeutic areas of medication addressed by the company are anti-allergic, gastroenterology, antiretrovirals, antibiotics, central nervous system and cardiology. With the market capitalisation valued at Rs. 37,281.76 crore on 15 June 2015, Aurobindo Pharma Limited is India’s fifth largest pharmaceutical company. Its products and services may be categorised as below:

    • Formulations
    • APIs

    Cadila Healthcare

    The city of Ahmedabad in the western Indian state of Gujarat is home to the head office of Cadila Healthcare that was founded in 1952. The company has around 20 different manufacturing locations across the country. Cadila Healthcare is India’s sixth largest pharmaceutical company in terms of market capitalisation that amounted to Rs. 36,159.61 crore on 15 June 2015. Its products and services may be categorised as below:

    • APIs
    • Formulations


    One of the oldest and most experienced players in the pharmaceutical industry of India, GlaxoSmithKline Pharmaceuticals Limited was established in 1924. GlaxoSmithKline Pharmaceuticals is one of the world’s top research-based health management and pharmaceutical companies. Major therapeutic areas of medication addressed by the company are anti-infectives, dermatology, oncology, gynaecology, diabetes, cardiology and respiratory products. In addition to that, it provides vaccines for cervical cancer, hepatitis B, hepatitis A, rota-virus, influenza, tetanus, chickenpox, pertussis and diphtheria amongst many. The market capitalisation of GlaxoSmithKline Pharmaceuticals Limited stood at Rs. 27,522.55 crore on 15 June 2015.

    Glenmark Pharmaceuticals

    Glenmark Pharmaceuticals is an Indian pharmaceutical company founded in 1977 and headquartered in Mumbai, Maharashtra. It specialises in developing and marketing APIs and formulations and covers segments such as diabetology, dermatology, ENT, internal medicine, gynaecology and paediatrics. Glenmark Pharmaceuticals is India’s eighth largest pharmaceutical entity by market capitalisation, which was valued at Rs. 25,045.36 crore on 15 June 2015. Its products and services may be categorised as below:

    • Formulations
    • Active Pharmaceutical Ingredients

    Divi’s Laboratories

    Divi’s Laboratories was set up in 1990 with the sole purpose of research and development in the life-sciences segment. The company mainly focuses on the development of modern innovative methods of manufacturing pharmaceutical intermediaries and other APIs. It is India’s ninth largest pharmaceutical company by market capitalisation, which amounted to Rs. 23,493.97 crore on 15 June 2015. Its products and services may be categorised as below:

    • Generics
    • Intermediates
    • Protected Amino Acids
    • Chiral Synthesis
    • Carotenoids (Synthetic) and Nutraceuticals

    Torrent Pharmaceuticals

    Based in Ahmedabad, Gujarat, Torrent Group’s flagship unit is Torrent Pharmaceuticals, founded in 1959. It is a major in therapeutic realms such as central nervous system and cardiovascular, spanning over segments like diabetology, gastroenterology and anti-infectives to name some. Torrent Pharmaceuticals is operational in over 50 countries and has a significant presence in India where it is rated as one of the top 10 pharmaceutical companies operating in the country. On 15 June 2015, the market capitalisation of Torrent Pharmaceuticals was Rs. 21,555.59 crore.

    Pharmaceutical Companies in India

    Industry Internships #euro #pharma

    #chicago pharmaceutical companies


    Industry Internships

    Gain new skills and experience a prospective career path by interning in a pharmaceutical company.

    Individual Internships

    Many senior graduate students explore potential career paths in a pharmaceutical or biotech company by arranging summer internships. Returning interns share their experience with other graduate students in a roundtable discussion scheduled in early fall. You can download a list of companies that offer internships. This list was put together by graduate students researching internships and is a work in progress. Below is the list of the companies where our students frequently intern.

    Hospira R D Professional Development Program

    Hospira is the world s leading provider of injectable drugs and infusion technologies. The Company is headquartered in Lake Forest, Illinois with approximately 17,000 employees worldwide and annual revenues over $4B.

    Now Accepting Applications to R D PDP Program.

    Deadline: October 9, 2015

    Include UIC in the Subject of the e-mail.

    Hospira/Pfizer Research and Development Professional Development Program Presentation and Interviews on October 27, 2015

    Hospira staff will be in the UIC College of Pharmacy to present their program to graduate students and postdocs. Presentation will be in room 134-3 from 9:30 am until 10:30 am. Breakfast will be provided. This will be followed by Q A session that will run until 11:30 am.

    Interviews: Pre-selected applicants will be invited for panel interviews on October 27. Interviews will be conducted from 12:30 until 5 pm.

    Hospira Research and Development (R D) Professional Development Program (PDP)

    The Hospira Research and Development (R D) Professional Development Program (PDP) is a graduate level program designed to provide accelerated training in the Pharmaceutical Research and Development (R D) field. The two year rotation program which leads to a full-time position within the organization offers real world, hands-on experience in important roles and projects to the company while promoting personal and professional growth for the participants.

    As a member of the PDP you will:

    • Deliver on key goals and objectives for the company and contribute to the overall success of the company.
    • Rotate through four demanding and diverse assignments in different disciplines within the various stages of the development life cycle.
    • Develop and enhance your communication skills supervising others, participating in meetings, and providing presentations to other Hospira personnel at all levels of the organization.
    • Gain experience working with cross-functional disciplines including Regulatory, Program Management, Operations, Engineering, Manufacturing and Quality.
    • Be assigned a mentor to provide guidance and oversight of your development in the program.
    • Obtain training to support your professional growth and development.
    • Have full time employee status with Hospira, Inc, and qualify for the same competitive salary and benefits as other Hospira employees.
    • Potentially be required to relocate to various Hospira manufacturing sites throughout the world as part of a rotation.

    Assignment Rotation:

    Core rotations: Early stage development, Generic Product Development, On-market product support.
    Options for additional assignments: Existing portfolio expansion to emerging markets, Program Management, Contract Manufacturing and Microbiology.


    • Graduate degree in Pharmaceutical Sciences, Chemistry, Pharmacy or equivalent.
    • Strong academic performance as demonstrated by research publications, presentations or equivalent.
    • Exceptional interpersonal skills and proven track record of teamwork, adaptability, innovation, leadership and initiative.
    • Qualified candidates must be interested in pursuing careers in R D within the pharmaceutical industry.
    • Rotation locations vary and thus the candidate must be willing to relocate for assignments

    Contact for more information:

    Home – Marinus Pharmaceuticals #pharmaceutical #companies #market #share

    #new pharmaceuticals


    Marinus is developing ganaxolone to improve the lives of
    patients with epilepsy and neuropsychiatric disorders

    Ganaxolone offers a new mechanism of action and is
    designed with selectivity and safety in mind

    Offering Continuity of Care

    The Right Treatment | The Right Formulation
    A Wide Range of Conditions

    Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.

    Press Releases

    Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results

    Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

    Latest Ajanta pharma ltd information at #pharma #research

    #ajanta pharma products


    Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. Committed to Serve Health Care Needs Worldwide. The company produces a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customised to each market, the company is present in. The company clearly understands customers needs and uses cutting edge technology to present innovative solutions. The companies business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.

    Established in 1973 and headquartered in Mumbai-India, the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up compact Manufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period between 1995 to 1998, the company established dedicated R
    /* 728×90, создано 05.02.11 */
    google_ad_slot = “6127977750”;
    google_ad_width = 670;
    google_ad_height = 90;

    Welcome to MWB Consulting – Your Pharmaceutical Development Experts #sami #pharma

    #pharma consulting companies


    As pharmaceutical development experts,
    MWB Consulting can engage with you in all phases of product development, regulatory approval and postmarketing compliance.

    P A R T N E R S

    MWB Consulting
    is the leading professional service company providing international clients with effective solutions for the development and postmarketing support of pharmaceutical products and devices. Our promise is to provide accurate and honest consulting advice allied to knowledge, efficiency and experience applied to the implementation of all our clients� projects.

    MWB Consulting provides superb drug development consulting services for our key programs.
    Medical Director,
    EU biotechnology company

    We are fortunate to have MWB Consulting as a partner.
    VP, Clinical Development,
    EU biopharmaceutical company

    MWB Consulting has given us excellent guidance on meeting our pharmacovigilance requirements in Europe.
    VP, Clinical Research and Development, US biopharmaceutical company

    Sales Representative (Pharmaceuticals) Salaries by education, experience, location and more #gland #pharma

    #pharmaceutical sales rep


    Sales Representative (Pharmaceuticals) Salaries

    Alternate Job Titles: Sales Representative (Pharmaceuticals), Sales Rep. (Pharmaceuticals)

    • What is the average annual salary for Sales Representative (Pharmaceuticals)?

      How much does a Sales Representative (Pharmaceuticals) make? The median annual Sales Representative (Pharmaceuticals) salary is $63,852. as of August 29, 2016, with a range usually between $42,073 – $71,437. however this can vary widely depending on a variety of factors. Our team of Certified Compensation Professionals has analyzed survey data collected from thousands of HR departments at companies of all sizes and industries to present this range of annual salaries for people with the job title Sales Representative (Pharmaceuticals) in the United States.

      This chart describes the expected percentage of people who perform the job of Sales Representative (Pharmaceuticals) in the United States that make less than that annual salary. For example the median expected annual pay for a typical Sales Representative (Pharmaceuticals) in the United States is $63,852, so 50% of the people who perform the job of Sales Representative (Pharmaceuticals) in the United States are expected to make less than $63,852.

      Source: HR Reported data as of September 2016

      • About this chart

        This chart describes the expected percentage of people who perform the job of Sales Representative (Pharmaceuticals) that make less than that salary. For example 50% of the people who perform the job of Sales Representative (Pharmaceuticals) are expected to make less than the median.
        Source: HR Reported data as of September 2016

        This is an incentive eligible position. Responsibilities include developing new prospects, establishing customers, and selling an organization s products and/or services. May require an associate s degree or its equivalent with 2-4 years of experience in the field or in a related area. Familiar with standard concepts, practices, and procedures within a particular field. Relies on limited experience and judgment to plan and accomplish goals. Performs a variety of tasks. Works under general supervision. A certain degree of creativity and latitude is required. Typically reports to a manager or head of a unit/department. View full job description

    Pharma websites #pharmajob

    #pharma websites



    Innate Pharma’s 2016 half year results with webcast on September 8, 2016

    Innate Pharma will announce its half year financial results for the six-month period ended 30 June 2016 on September 8 at 7am CEST.

    The management team of Innate Pharma will host a conference call at 14.30 CEST on the day of the results. The call will be conducted in English and a replay will be available on the “Innate Live” section of the website after the conference call.

    To access the conference call at 14.30 CEST, please dial:

    +33 (0)1 70 77 09 35

    Innate Pharma acquires full rights to ANTI-NKG2A

    Innate Pharma in Biocentury Innovations

    In the July 28 2016 issue of Biocentury Innovations, Innate Pharma is interviewed in the cover story entitled “INNATE HARMONY” explaining why NK cells are the next big thing in immuno-oncology.

    Innate Pharma acquires full rights to ANTI-NKG2A

    Investor Analyst Update on May 16th, 2016, in New York, USA

    Innate Pharma’s management team gave an overview of the Company’s pipeline of first-in-class monoclonal antibodies in Immuno-Oncology and provided an update on the Company’s strategy.

    The event was intended for institutional investors and sell-side analysts only.

    A webcast replay is accessible at

    Innate Pharma acquires full rights to ANTI-NKG2A

    What the Latest FTC Guidelines Mean to Pharma Marketers #history #of #pharmaceutical #industry

    #pharma guidelines


    What the Latest FTC Guidelines Mean to Pharma Marketers

    As pharma marketers, we tend to listen closely when the U.S. Food and Drug Administration (FDA) issues guidance, such as their draft guidance on correcting misinformation online. and user-generated content. In June this year, however, it was guidelines from the Federal Trade Commission (FTC) that got our attention.

    The updates published via the agency s frequently asked questions and social media marketing guidelines focus primarily on testimonials and endorsements. With the rise in popularity of product reviews, the FTC is interested in ensuring consumers can clearly tell the difference between an honest third-party review and a paid endorsement. This has implications for pharmas who work with consumers and HCPs to provide paid testimonials or endorsements.


    In its first update to the social media marketing guidelines since 2010, the FTC released several guidelines on how to participate in social media when endorsing a product or service, or paying someone to do so on your behalf. The overall goal of the guidelines is to ensure consumers can clearly identify what is marketing and what is an authentic consumer review or endorsement.

    The update could impact employees of a company who talk about their products or services online, as well as pharmaceutical companies that work with patient advocates, influencers or KOLs. The guidelines apply to both reviews of the product and any subsequent services, such as patient programs that those individuals may represent.

    The updated guidance focuses on three key aspects of endorsements:

    • What an endorsement is and who an endorser is/can be
    • What the endorsement can and should include
    • How to represent yourself if you are an endorser


    Within the update, the FTC clearly states what qualifies as a (paid) endorsement, as well as who an endorser is:

    An endorsement means any advertising message (including verbal statements, demonstrations, or depictions of the name, signature, likeness or other identifying personal characteristics of an individual or the name or seal of an organization) even if the views expressed by that party are identical to those of the sponsoring advertiser. The party whose opinions, beliefs, findings, or experience the message appears to reflect will be called the endorser and may be an individual, group, or institution.

    For pharmaceutical companies, this could apply to patient advocates who represent the brand, employees of that company and/or any agency that represents them.


    Above all, the FTC requires that paid endorsements be accurate and honest. Anyone who is paid to endorse a product or service must be a bona fide user of that product or service at the time of the endorsement. Additionally, when a consumer is paid to endorse his or her experience with a product or service, they must cite substantial facts and figures that validate their experience. A paid endorser cannot make claims about a product that requires proof the company doesn t have, and they must disclose that their experience is not typical.


    It is important to provide clear direction to your paid endorsers. Anyone paid to endorse or represent a product or service must clearly and conspicuously disclose any and all material connections to the company. Any connection between an endorser and the company that consumers would not expect and that might affect how consumers evaluate the endorsement must be disclosed. To make a disclosure clear and conspicuous :

    • For print or web, it must be:
      • Close to the claims to which they relate
      • In a font that is easy to read
      • In a shade that stands out against the background
    • For video ads, it must be:
      • On the screen long enough to be noticed, read and understood
    • For audio disclosures, it must be:
      • Read at a cadence that is easy for consumers to follow and in words consumers will understand

    Disclosures should include any sort of payment received, including free products. However, this guidance does not require the endorser to disclose how much compensation they received.


    Also in June, the FTC made several updates and additions to its What People Are Asking page on its website. The page is intended to provide answers to questions about the FTC s Endorsement Guides. which provide information and direction on ensuring product endorsements remain honest and do not mislead consumers.

    The updates to the FAQ focus primarily on the implications of endorsements in social media and include an emphasis on character limits, contests and giveaways, sharing content (including images) on social networks, and video content. Pharmaceutical companies that work with patient advocates who use social networks should evaluate how they are promoting those advocates. Any paid influencers speaking on a pharma s behalf must clearly and accurately disclose their relationship when they post, comment or share on social networks.

    The full FAQ can be found on the FTC website here ; below is a summary of the direction that most often affects pharmaceutical marketing.

    1. Know your medium. The FTC has clearly laid out guidelines for newer social networks not previously adressed, including Twitter and Pinterest. Character limitations on any social network, including the 140-character limit on Twitter, are no longer and adequate reason for not presenting users with all the information they need. Clear disclosure language must be present in any tweet from a paid endorser or any tweet promoting a contest or giveaway. Additionally, sharing a link on a social network via a Share button requires a disclosure if you are a paid influencer or employee of that company. This also applies to images that are shared without text, specifically those that are shared via the Pin It button for Pinterest.
    2. Evaluate video content. The FTC also updated guidelines on video content that features a paid endorser. Any video endorsements must have a clear and conspicuous disclosure within the actual video and not just in the description. The FTC defines clear and conspicuous as on the screen long enough to be noticed, read, and understood. For pharmaceutical companies that feature patient advocates in video marketing efforts, disclaimer language must be included in each individual video.
    3. Employees are endorsers, too. Employees of a pharmaceutical company, including any employees at ad agencies or PR firms that represent them, are considered paid endorsers if they are talking about the company s products or services. Any employee doing so must clearly identify their relationship in each post, and a sentence in their social media profile is not sufficient disclosure. Pharmaceutical companies should develop clear social media guidelines for all employees and agency affiliations.

    With the updates to both the social media marketing guidelines and the FAQ, the FTC clearly states what constitutes an endorser and how to treat communication that comes from them. This impacts pharmaceutical companies in several ways:

    • Pharmaceutical companies that run patient advocate and KOL programs should evaluate any communication these representatives make on behalf of the company. Pharma marketers should work with their agencies to provide direction including clear language for them to follow. This includes ensuring payment and connections between the company and patient are disclosed in any endorsement.
    • Pharmaceutical companies that produce videos and images and run contests through social media should review those programs to ensure they are in line with FTC guidance.
    • Employees of a pharmaceutical company are considered endorsers when they talk about a product or service online, even if they are not specifically paid to do so. They must disclose their relationship with the company when interacting online. This guidance also extends to agencies that represent the pharmaceutical company.

    As communication and advocacy evolve in a social age, so must pharma marketers. Intouch Solutions will continue to monitor additional guidance and publish updates as appropriate.

    For more information and ideas about working with influencers and advocates in a compliant manner, contact your Intouch Solutions representative.

    The information contained in this document is for general guidance on matters of interest only. Intouch Solutions makes no representations as to the accuracy or any other aspect of information contained in linked websites. The information contained in this document is not, nor is it intended to be, legal advice.


    Novartis Pharma en France: recherche et innovation au service des patients #online #pharma

    #novartis pharma


    Neurologie Informations et conseils l’attention des patients atteints de la maladie de Parkinson. Conseils aux patients et leur entourage visant optimiser la prise en charge de la scl rose en plaques (SeP). Site pour les patients atteints de scl rose en plaque et leur entourage

    Pneumologie Site destination des patients atteints de Broncho-Pneumopathie Chronique Obstructive (BPCO) et leur entourage.

    Ophtamologie Plateforme d informations pour les patients atteints de D g n rescence Maculaire Li e l ge (DMLA) et leurs proches.

    Dermatologie Informations, actualit s et conseils l’attention des patients atteints d urticaire ou de psoriasis et de leur entourage. Informations sur la Journ e Mondiale de l Urticaire l attention des patients atteints d urticaire et de leur entourage. Site institutionnel de Novartis en France. Concours destin aux tudiants des coles de journalisme dans le domaine de la responsabilit citoyenne. D couvrez G n ration Proches. durant une ann e, journalistes et photographes m neront des investigations au plus pr s du terrain, travers un v ritable tour de France des r gions. Leurs travaux permettront de mieux comprendre les modes de vies et les attentes de l entourage des personnes malades ou d pendantes. Conseils, informations pratiques, t moignages et services pour les proches de personnes rendues d pendantes par la maladie, le handicap ou bien le grand ge. Site destin aux professionnels de sant et chercheurs, concernant les relations entre les personnes malades et leur entourage. Viaopta est une plateforme destination des ophtalmologistes et du grand public. Elle met leur disposition des informations sur diff rentes maladies des yeux, dont la DMLA (d g n rescence maculaire li e l’ ge), ainsi que des avis d’experts et des services li s l’ophtalmologie. Ce site est d di l am lioration de la prise en charge des patients vieillissants.

    How Novartis Pharma Business Split Will Impact its Business (NVS, GSK) #alliance #pharma

    #novartis pharma


    How Novartis Pharma Business Split Will Impact its Business (NVS, GSK)

    In the wake of another high-profile exit, Novartis ( NVS ) is undergoing an ambitious new strategy and restructuring its business divisions. (For more, see: Interested In Pharmaceutical Stocks? Try Novartis (ADR) . )

    The Developments

    In a recent press release. the company announced two changes, which will be effective on July 1, 2016.

    First, David Epstein, who heads the American pharmaceuticals division for Novartis, will leave after a 27-year long tenure at the company.

    Second, the company is splitting its $49.4 billion pharmaceuticals division into two separate units, Novartis Oncology, and Novartis Pharmaceuticals, both folding under the Innovative Medicines unit. Novartis Oncology will be dedicated to cancer drugs and will be headed by Bruno Strigini. While Novartis Pharmaceuticals will encompass the firm’s other drugs and will be directed by Paul Hudson, who comes to the company from AstraZeneca. This development goes in sync with Novartis’ $16-billion purchase of GlaxoSmithKline’s (GSK ) cancer drugs unit last year and indicates the company’s focus on the growing significance of oncology medicines.(For more, see: Glaxo in $1 Billion Ofatumumab Deal With Novartis .)

    With this change, the company will have three consumer-focused business units: Innovative Medicines, comprising of Novartis Oncology and Novartis Pharmaceuticals; Sandoz, comprising of Retail Generics, Anti-Infectives and Biopharmaceuticals franchises; and Alcon, the eye care devices division. (For more, see: How Novartis Makes Money .)

    The Market Voices

    There are mixed opinions about the Novartis developments, as the company faces several challenges.

    For example, the patent for the blood cancer drug Glivec is expiring, which could lead to a loss of exclusive revenue in coming times. Thus, how this new cancer drug specific unit would shape up remains an open question.

    Also, t he company recently restructured its Alcon eye care division, leading to the departure of the division’s head, Jeff George.

    Additionally, while the outgoing executive, David Epstein, is credited with the successful launch of blockbuster drugs like Glivec, Gilenya, and Cosentyx, his tenure also accounts for the failure of Entresto, the much-touted heart failure drug which missed expected sales. According to Bloomberg. “Analysts cut their 2020 sales estimates for Entresto by 35 percent, or $2.1 billion.” However, Novartis continues to remain bullish on Entresto, with a peak projected sale target of $5 billion.

    That said, the new head of Novartis Pharmaceutical division, Paul Hudson, is credited with successful launch and marketing of AstraZeneca’s Brilinta, which had similar sales challenges. His experience is expected to help revive the marketing of Entresto.

    The Bottom Line

    Cancer drugs constitute the majority of the company’s business, so running cancer drugs as an independent division will allow for smoother operations. However, the restructuring comes at a time when Novartis seems to be struggling to cut costs, integrate GSK’s drug unit, and revive sales of major drugs. The impact of these most recent changes will be visible over a long-term period. Following the new announcements, no significant changes were observed in the share price of Novartis though, indicating a neutral response from the markets.

    Pharmaceutical Purified Water Newsletter» – N° 8 to 10 – METTLER TOLEDO #global #healthcare #companies

    #pharma newsletter


    «Pharmaceutical Purified Water Newsletter» – N° 8 to 10

    Perspectives in Pure Water Analytics

    Below to this section you can find the «Pharmaceutical Purified Water News» in English for download in pdf-format. The newest release will always be placed on the bottom of the page.

    For more information on our pure water analytics solutions within the pharmaceutical USP industry, you can contact us by using the feedback button on the bottom of this page. We will be happy to assist you!

    «Pharmaceutical Purified Water News» N° 8 (12/06) – Headlines:

    • High Performance Ozone Measurement
      for Pharmaceutical Water Production
    • Training and Technical Services:
      On-site instrumentation and calibration
      training workshops

    «Pharmaceutical Purified Water News» N° 9 (06/07) – Headlines:

    • Implementation of the Multiparameter
      Concept in Pharmaceutical Water Preparation
    • TOC and Conductivity Measurements
      for Improved WFI Quality
    • Training and Technical Services

    «Pharmaceutical Purified Water News» N° 10 (12/07) – Headlines:

    • Are You Testing Your Pure Steam
      for Conductivity and TOC?
    • 5000TOC Sensor – Accurate TOC
      Measurements in Real-Time
    • Training and Technical Services

    Pharmaceutical Purified Water Newsletter» – N° 4 to 7 – METTLER TOLEDO #pharma #recruiters

    #pharma newsletter


    «Pharmaceutical Purified Water Newsletter» – N° 4 to 7

    Perspectives in Pure Water Analytics

    Below to this section you can find all available «Pharmaceutical Purified Water News» in English for download in pdf-format. The newest release will always be placed on the bottom of the page.

    For more information on our pure water analytics solutions within the pharmaceutical USP industry, you can contact us by using the feedback button on the bottom of this page. We will be happy to assist you!

    «Pharmaceutical Purified Water News» N° 4 (12/04) – Headlines:

    • Simplicity, the key to C lean-I n-P lace measurement
    • Conductivity instruments meet USP purified water,
      highly purified water, and WFI requirements
    • Training and technical services: On-site instrument operation
      and calibration training workshops

    «Pharmaceutical Purified Water News» N° 5 (07/05) – Headlines:

    • The 5000TOC Sensor adds online TOC measurement
      capability to 770MAX
    • THORNTON now provides configuration and data logging
      software for the 770MAX
    • Training and technical services: On-site instrument
      operation and calibration training workshops

    «Pharmaceutical Purified Water News» N° 6 (12/05) – Headlines:

    • Purified Water for emergency eye wash stations –
      THORNTON now provides configuration and data
    • PAT initiatives and TOC measurements for higher
      product quality and profitability
    • Training and technical services

    «Pharmaceutical Purified Water News» N° 7 (06/06) – Headlines:

    • System suitability testing:
      Simplifying a critical element in the TOC monitoring process!
    • What’s new in the world of pure water requirements?
    • Training and technical services

    About Apotex #akela #pharma

    #pharmaceutical companies in canada


    About Apotex

    Our Mission

    APOTEX is an independent, dynamic, Canadian pharmaceutical company committed to R D, manufacturing and distributing a broad range of high-quality, affordable medicines to patients, healthcare providers, payers and governments worldwide. We will always meet global regulatory, quality and compliance requirements. We value and respect our employees, our business partners, our suppliers, our customers and the communities we serve while operating with accountability and integrity in everything we do.

    Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 10,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies has over 6,000 employees. Extensive investments in Canadian facilities include over 3 million square feet in manufacturing and R D facilities in Richmond Hill, Toronto, Etobicoke, Brantford, Windsor and Winnipeg. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 89 million prescriptions a year – the largest amount of any pharmaceutical company in this country.

    Today, Apotex is a necessary and trusted member of Canada’s healthcare community. The company’s pharmaceuticals can be found in virtually every pharmacy and healthcare facility in Canada and are exported to over 115 countries around the globe. Export markets represent an ever growing portion of the total sales. Apotex has also established a presence through subsidiaries, joint ventures or licensing agreements in Australia, Belgium, Czech Republic, Mexico, Netherlands, New Zealand and Poland to name just a few. Healthcare professionals around the world rely on Apotex for quality and value.

    Although the company’s own business is developing and manufacturing generic pharmaceuticals, the success of Apotex has enabled it to diversify into a number of other health-related areas. The Apotex Pharmaceutical Group of Companies also researches, develops, manufactures and distributes fine chemicals, non-prescription and private label medicines, and disposable plastics for medical use.

    The worldwide sales of the Apotex Group of companies exceed $2 billion (Canadian $) per year.

    Begin breadcrumb – You are here:

    Home About Apotex

    Injury statistics in the pharmaceutical industry #new #pharmaceuticals

    #pharmaceutical industry statistics


    Injury statistics in the pharmaceutical industry

    How big is the problem in the pharmaceuticals industry?

    The Health and Safety Executive (HSE) collate ergonomic injury data submitted through reportable accidents and diseases (RIDDOR reports). This data has been analysed to show the most common types of injury occurring within the pharmaceutical industry.

    The following graphs relate to the RIDDOR reports submitted to the HSE between 2001 2004 from the pharmaceuticals sector.

    Incidence of reported occupational injury

    Manual handling incidents were the most frequently reported RIDDOR, with upper limb disorders being third most frequent.

    Incidence of reported upper limb disorders

    Cramp and tendon inflammation are the most commonly reported upper limb disorder.

    Body areas injured due to manual handling

    The back is most commonly injured during manual handling, followed by the upper limbs.

    Pharmaceutical companies in canada #sinclair #pharma

    #pharmaceutical companies in canada



    In addition to Pharmaceuticals, the Johnson Johnson Family of Companies includes Consumer, Medical Devices and Diagnostics companies.

    The values that guide our decision-making are spelled out in Our Credo. Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.

    Robert Wood Johnson, former chairman and a member of the Company’s founding family, crafted Our Credo himself in 1943. Our Credo represents a set of values that the Johnson Johnson companies still live by. Our Credo is more than just a moral compass. We believe it’s a recipe for business success.

    People Development and Collaboration

    At Janssen, we work to create a collaborative, innovative, diverse, ethical and inclusive culture. Our employees describe their work experiences at Janssen as challenging, rewarding, interesting and fulfilling.

    Janssen puts a premium on individualized development and has a learning curriculum that offers a variety of professional development opportunities to employees. We have a strong focus on leveraging employees’ strengths – and enabling employees to learn how to apply their individual strengths to their business interactions with colleagues.

    We want every Janssen employee to be deeply committed and passionate about their work, and our comprehensive engagement strategy helps us to achieve this.

    We are one team working together for patients every day.

    Innovation is a key focus for Janssen and a critical part of our culture. Innovation is about approaching our jobs in new and different ways that add incremental wealth and/or value to Janssen. Training and development help employees imbed innovation into everyday thinking and program development, implementation and results.

    Diversity and Inclusion (D I)

    Our commitment to diversity and inclusion is deeply rooted in the values instilled by Our Credo. People and values are our greatest assets. We know that every product and every breakthrough we’ve brought to human health and well-being has been powered by people. Not ordinary people, but people whose personal values drive them to make a difference in the world.

    We believe attracting, retaining and utilizing diverse talent and providing an inclusive culture are essential to Janssen’s success. This diversity of thinking, backgrounds and experiences enables us to develop strategies and insights that help to shape our marketplace.

    Janssen is the leading pharmaceutical company in Canada, with a head office in Toronto, Ontario. As the industry leader, Janssen has a responsibility to proactively shape our industry and is actively involved with Rx D (representing Canada’s research-based pharmaceutical companies).

    We estimate that the Johnson Johnson Family of Companies worldwide touch more than a billion people’s lives each day through our healthcare products and services, our corporate giving and the volunteer efforts of our employees.

    For more information and to apply, please visit:

    EMEA finalises EU pharma guideline procedure #pharma #company #jobs

    #pharma guidelines


    EMEA finalises EU pharma guideline procedure

    By 01-Jul-2005 2005-07-01T00:00:00Z

    The European Medicines Agency (EMEA) has finalised a new procedure designed to make the process for the development, consultation, finalisation and implementation of pharmaceutical guidelines clearer.

    The response by Europe’s main pharmaceutical regulatory body, aims to tighten up and clarify new guidelines, keeping in line with the European Union’s harmonisation activities with Japan, US and other international partners through the international conferences on harmonisation for human and veterinary medicines (ICH and VICH).

    The procedure was drawn up in an attempt to give guidance to applicants and/or sponsors planning the overall pharmaceutical product development. In addition, they were intended to facilitate the preparation of applications for marketing authorisations by the pharmaceutical industry.

    Pharmaceutical guidelines provide essential information to be taken into account in the research and development of new medicines. Based on the most up-to-date scientific knowledge they are a part of the Agency’s work within the European Union pharmaceutical regulatory system.

    Indeed, with the recent issues concerning clinical trial procedures and safety concerns involving blockbuster drugs, the procedures could well have been devised as a response to these events.

    The EMEA also said that the procedure was important in assessing the impact for interested parties and competent authorities. In addition, the new procedure related to how decisions were taken on whether new guidance was needed.

    The improvements to the current guideline procedures are part of the Agency’s response to the transparency consultation exercise carried out in 2003. A draft version was released for consultation in September 2004.

    The draft: Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework, is available on the EMEA website .

    Related News

    EU drug approvals neglect rare disease treatments

    Our Services to the Pharmaceuticals and Life Sciences Industry, PwC Canada #gmp #pharma

    #pharmaceutical companies in canada


    Pharmaceuticals and Life Sciences

    Helping the business of health by improving the health of business

    Is it any surprise that Canada’s life sciences and pharmaceutical industry receives one out of every four dollars of venture capital investment? After all, an aging Canadian population has significantly increased demand for health-related products and treatment, and the sector is working hard to keep up. With the global pharmaceutical market predicted to double to $1.8 trillion by 2020, there is a lot at stake for Canadian players in this sector.

    Yet there are unique challenges facing our life sciences and pharmaceutical industry. Canadian patent rules are inconsistent with those in the United States, leaving many companies with less time to fully realize the value from their intellectual property. Canadian companies are also subject to complex regulatory regimes, and this can hamper innovation as the industry shifts focus from health treatment to preventative care.

    As a Canadian life sciences or pharmaceutical company, you face many issues that affect both short-term and long-term strategies for your business growth. These can include:

    How we can help

    PwC offers a range of services that can help you tackle the complex issues impacting the Canadian life sciences and pharmaceutical sector. We offer help with corporate governance issues, regulatory compliance, information technology effectiveness, human resource solutions and benchmarking. We also have a wide network of contacts in the venture capital and private equity sectors and can quickly put you in touch with the people you need to know. Contact us today to see how we can help you.

    Of further interest


    Canadian Corporate Tax, Corporate Restructuring

    Tax, Pharmaceuticals, Life Sciences

    Prabh Singh, CA


    Oakville Ontario

    • Canadian Corporate Tax
    • Corporate Restructuring

    Partner Tel: +1 905 815 6405 Email

    Medical Product Compliance, Regulatory, Validation #valeo #pharma

    #pharma tech



    Your products touch lives. At Pharmatech Associates, we help life science companies bring these products to market worldwide. Navigating the complex and interconnected regulatory processes require technical expertise in compliance, product and process development, validation, and regulatory affairs. We call this the Pharmatech Ecosystem.

    And that means better outcomes for our clients’ patients.


    Our Subject Matter Experts have fully integrated development knowledge, hands on experience, and the ability to respond rapidly with pragmatic solutions, by applying proven and effective systems and practices. Our diligence in managing budget and timeline processes provides measurable value. As a result, our clients consistently rank us in the top-tier of life sciences industry consultants providing similar services. For Pharmatech, this has translated into a customer retention rate among the best in the industry, with some clients choosing to partner with Pharmatech since its inception in 1995.



    Our Subject Matter Experts have fully integrated development knowledge, hands on experience, and the ability to respond rapidly with pragmatic solutions, by applying proven and effective systems and practices. Our diligence in managing budget and timeline processes provides measurable value. As a result, our clients consistently rank us in the top-tier of life sciences industry consultants providing similar services. For Pharmatech, this has translated into a customer retention rate among the best in the industry, with some clients choosing to partner with Pharmatech since its inception in 1995.


    The Pharmatech Difference

    Bikash Chatterjee, President and Chief Scientific Officer, introduces you to the breadth and depth of knowledge and expertise possessed by our staff of Associates and SMEs at Pharmatech, and explains our unique approach to advising and providing technical services to our clients, that has been the basis for our decades of success in the Regulated Life Science industry.


    “Thank you again for endurance during the contract process, etc. From my view, the meeting finished in success, thank you for two wonderful members you have introduced to us. The Client felt that they were able to receive valuable comments surpassing what they have paid for.”


    “Pharmatech’s team has been a crucial element to the success of the project. Pharmatech was originally brought on to perform commissioning and qualification activities of the facility, utilities, and process systems related to the product. As the project commenced, Pharmatech’s engineers and project manager provided much more to ensure the project was completed successfully. Pharmatech became an integral member of our team, assisting with troubleshooting and creating solutions in order to complete the installation, optimization, and operation of key process systems. Most notably was a fluid bed granulator and solvent coater and their associated systems. I have very high praise for Pharmatech’s work as they not only execute the work well, but they also provide answers rather than wait for solutions to be presented to them during the course of the project.”

    – Johnson and Johnson Division

    “Thank you so much for all you and your team’s work in our facility, there is no way we could have done this without you.”

    The Best Pharma ETF #cafe #pharma #novartis

    #big pharma etf


    The Best Pharma ETF

    Sep. 12, 2014 12:36 PM

    • PPH is a mega cap fund with foreign exposure.
    • IHE is a domestic fund with some small and mid-cap exposure.
    • XPH is a fund that equally weights across holdings and is relatively balanced across market cap.
    • PJP is the best performer since 2006.

    Investors have four ETF options in the pharmaceutical sector with sufficient assets and trading volume. Which one is the best of the bunch? It turns out they all have unique properties, but one stands out from the pack due to its outperforming the group.

    PowerShares Dynamic Pharmaceuticals (NYSEARCA:PJP )

    PJP tracks the Intellidex index, one of the first “smart” indexes in the ETF market. The fund passively tracks the index, by criteria such as growth, valuation and momentum.

    SPDR S P Pharmaceuticals (NYSEARCA:XPH )

    XPH tracks the S P Pharmaceuticals Select Industry Index, a market cap weighted index.

    iShares U.S. Pharmaceuticals (NYSEARCA:IHE )

    IHE tracks the Dow Jones U.S. Select Pharmaceutical Index, which is a “float-adjusted market capitalization subject to caps on the weights of the largest securities.”

    Market Vectors Pharmaceutical (NYSEARCA:PPH )

    PPH tracks the Market Vectors US Listed Pharmaceutical 25 Index, which takes the 50 largest pharma companies and then selects the top 25 by free-float market capitalization.

    The cheapest funds are XPH and PPH, with expense ratios of 0.35 percent. IHE is not far behind at 0.46 percent; PJP is relatively expensive at 0.63 percent.

    For investors looking for income, PPH leads the pack with a 1.75 percent 30-day SEC yield. IHE yields 1.05 percent; XPH yields 0.70 percent; PJP yields 0.48 percent.

    Of the four funds, XPH is the most diversified across its holdings. It has 34 holdings and equally weights them, with the largest holding currently Salix Pharmaceuticals (NASDAQ:SLXP ). It also has assets pretty evenly split across large, mid and small cap. This gives XPH the smallest average market capitalization of that group at $8 billion.

    There are two main differences between PPH and IHE. First, PPH holds foreign drug makers such as Novartis (NYSE:NVS ) and Sanofi (NYSE:SNY ). In total, 40% of PPH’s portfolio is overseas, versus the domestic portfolio of IHE. Second, PPH is a mega cap fund, with an average market cap above $100 billion. IHE has some mid- and small-cap holdings that reduce its average market cap to $24 billion.

    Both PPH and IHE weight their holdings similarly. PPH has 61 percent of assets in its top 10 holdings and IHE has 63 percent.

    PJP is diversified across its holdings, with 5 percent of assets in top holding Pfizer (NYSE:PFE ) and 2.94 percent in Salix Pharmaceuticals. Since PJP uses a “smart” index, the portfolio can change substantially at each rebalancing. Currently, PJP has very little in mid-caps, about 30 percent in small-caps and the rest in large caps, giving it an average market capitalization of $20 billion.

    Three of the pharma ETFs have histories going back more than 8 years. PPH changed its index in 2011 (it was formerly the Pharma HOLDRs).

    Here’s what the long-term performance looks like for the other three funds, starting from the end of 2006.

    PJP is the clear winner, followed by XPH and then IHE.

    Since inception in late 2011, here is how all four have performed.

    When evaluating a “smart” index like PJP, performance is one of the major criteria because the portfolio can change substantially over time. PPH will still be a mega cap fund with a large allocation to foreign pharma stocks in future and IHE will still be domestic, while XPH will still have its equal weight approach that delivers a lot of mid- and small-cap exposure. If mega cap pharma stocks lead the market, PPH should lead and XPH should trail. When the trend reverses, relative ETF performance will reverse with it. For example, it’s clear in the second chart that small cap weakness in March, April and July of this year hurt XPH.

    With PJP and other “smart” indexes, there’s no way to know what the portfolio will look like in several months time, let alone several years. Either the index works, and outperforms, or it doesn’t. Given the track record of PJP, it appears the Intellidex strategy works in the pharmaceutical sector.

    PJP is not flawless though. During the bear market of 2008 and even several months into the recovery in 2009, PJP lagged the other funds by a significant margin. It may be that the price-momentum factors did not serve the model well, but whatever the reason, PJP has underperformed for an extended period.

    Investors have four options in the pharmaceutical space and all four have something to recommend them. XPH offers the most small-cap exposure and its equal weight approach is good news if one of those small-caps hits a homerun; XPH is also among the cheapest funds.

    PPH is tied for being the cheapest with XPH. It offers mega cap, global exposure to the pharma industry, with the highest yield of the group.

    IHE delivers domestic pharma exposure with a portfolio more diversified by market capitalization than PPH.

    PJP offers a “smart” index strategy for passive investors who don’t want to analyze which of the other three funds are best positioned to outperform in the next year. However, given its track record, which of course does not guarantee future results, PJP also makes a strong argument that it is the best of the group for long-term investors.

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

    Read full article

    Russian and Chinese pharmaceutical companies are ready for greater cooperation #pharma #ad #agencies

    #chinese pharmaceutical companies


    Russian and Chinese pharmaceutical companies are ready for greater cooperation

    The direction on a strategic partnership between Russia and Chiba is not a temporary campaign but rather a policy that was precisely evaluated over the history of our cooperation. It is time to consider a more deep partnership in several erase such as education, science, and production of a globally competitive goods, said ARPM Director General, Victor Dmitriev at the Russia- China Dialogue that took place at the Russian Chamber of Commerce.

    Trade and economic relationships between the two countries have been developing over decades. Today the commodity turnover is over $68 billion of which $33 billion is the Russia s export into China and $35 billion Chinese export into Russia.

    “The pharmaceutical commodity turnover reached $1.5 billion in 2015. Most of it

    accounted for the import of pharmaceutical substances from China. However, the US Dollar still remains the single exchange currency between the two countries. It is time escape dependence on the US Dollar, especially after the new idea that the Chinese Yuan should become Russia’s reserve currency,” noted Mr. Dmitriev.

    The Chinese counterpart also tuned on the deeper level of interaction. Deputy chairman of the Association of Industrialists and traders in Heilongjiang Province, Chen Weiming noted the Summit Russia-ASEAN, the Innoprom exhibition and other events of the past months have proven that Russia is not only the closest neighbor, but also the main economic partner, and cooperation with Russia has a great potential.

    Chinese counterparts are confident that Russia and China have great potential to mutually fulfill each other’s markets. Russia produces a lot of raw materials and finished pharmaceutical products. Chinese manufacturers are interested in purchasing those products as well as Russian business is interested in Chinese goods, according to Deputy Chairman of the Pharmaceutical Chamber of the All-China Association of Industry and Commerce, Zhao Syan. It is important to work together to improve the logistics between the two countries and to broaden our import-export relationships.

    The Russia delegates agreed with their Chinese counterparts and shared a confidence that the developed contacts will grow into mutually beneficial business agreements.

    Pharmaceutical GMP Professional Certification (CPGP) #aventis #pharma

    #gmp pharma


    Pharmaceutical GMP Professional Certification – CPGP

    Retakes: $298* (no discounts)

    The Certified Pharmaceutical GMP Professional understands the GMP principles as regulated and guided by national and international agencies for the pharmaceutical industry. This covers finished human and veterinary drugs and biologics, ectoparasitacides, and dietary supplements (alternatively called nutraceuticals where regulated as drug products, as well as their component raw materials (includes active pharmaceutical ingredients (APIs) and excipients), and packaging, and labeling operations.

    1. Is this the right certification for you?
    Understand the minimum expectations, requirements, experience, and the exam specifics for a Pharmaceutical GMP Professional.

    3. Choose an exam date.
    Find the best date and location that works for you. (Note the application deadlines for each exam date.)

    4. Apply for certification.
    ASQ offers several ways to apply. Have your r sum and credit card ready.

    5. Recertify.
    ASQ requires that you recertify as a Certified Pharmaceutical GMP Professional every three years either by documenting RU credits or by testing.

    *$70 of your fee is an application fee, and is not refundable

    Sign In

    Did You Pass?

    Pharmaceutical GMP Professional Certification

    American Society for Quality. All rights reserved.

    Breaking World Pharma News #pharma #clinical #trials

    #pharmaceutical news


    10th European Medical Information and Communications Conference and Exhibition

    29 – 30 November 2016. Berlin, Germany
    The 10th year of the Annual European Medical Information and Communications Conference is a unique meeting organised by medical information professionals for medical information professionals. Each year, speakers share hands-on experience dealing with current challenges as well as successes in medical information departments.

    Last Updated: Saturday, 03 September 2016

    Antibody reduces harmful brain amyloid plaques in Alzheimer’s patients

    Although the causes of Alzheimer’s disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons between ten and fifteen years before the emergence of initial clinical symptoms such as memory loss. Researchers have now been able to show that Aducanumab, a human monoclonal antibody, selectively binds brain amyloid plaques, thus enabling microglial cells to remove the plaques.

    Last Updated: Saturday, 03 September 2016

    Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma

    Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.

    Last Updated: Friday, 02 September 2016

    Caffeine and its analogues revert memory deficits by normalizing stress responses in the brain

    A study published in the journal Scientific Reports from Nature publishing group, describes the mechanism by which caffeine counteracts age-related cognitive deficits in animals. The study coordinated by Portuguese researchers from Instituto de Medicina Molecular (iMM Lisboa) and collaborators from Inserm in Lille, France, along with teams from Germany and United States,

    Last Updated: Wednesday, 31 August 2016

    Less efficacy than expected in largest drug-eluting stent trial

    New generation drug eluting stents (new DES) did not outshine contemporary bare metal stents (BMS) as they were expected to, in a surprise finding of the largest randomized stent trial to date. The Norwegian Coronary Stent Trial (NorStent), presented at ESC Congress 2016, and published simultaneously in the New England Journal of Medicine, “demonstrates that the efficacy of new DES versus contemporary BMS is lower than expected,”

    Last Updated: Wednesday, 31 August 2016

    Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia

    Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia.

    Last Updated: Wednesday, 31 August 2016

    Vitamin C may boost effectiveness of acute myeloid leukemia treatment

    A simple adjustment to patients’ therapeutic regimen may improve the effectiveness of the standard epigenetic treatment for myeloid dysplastic syndrome (MDS) and acute myeloid leukemia (AML). New findings published today in the Proceedings of the National Academy of Sciences showed in lab studies that supplementing an epigenetic cancer drug called decitabine with vitamin C enhanced the drug’s ability to

    Last Updated: Tuesday, 30 August 2016

    Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp

    Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international universities will discuss and explore with biotechnology and business experts how patients around the world can benefit from innovative technologies.

    Last Updated: Monday, 29 August 2016

    Discovery of a novel Wnt inhibitor with potential to eradicate colorectal cancer stem cells

    A team including the National Cancer Center (NCC) (Tokyo, Japan), the RIKEN Center for Life Science Technologies (CLST) (Yokohama, Japan), and Carna Biosciences Inc. (Kobe, Japan) has jointly announced the development of a novel small-molecule Wnt inhibitor named NCB-0846. Wnt signaling is a key pathway of cancer stem cell (CSC) development.

    Last Updated: Friday, 26 August 2016

    Breast milk sugar may protect babies against deadly infection

    A type of sugar found naturally in some women’s breast milk may protect new born babies from infection with a potentially life threatening bacterium called Group B streptococcus, according to a new study from Imperial College London. These bacteria are a common cause of meningitis in new borns and the leading cause of infection in the first three months of life in the UK and globally.

    Last Updated: Friday, 26 August 2016

    Pharma Industry

    #pharma industry


    Pharma Industry / Biotech Industry News

    The latest pharma industry and biotech industry research from prestigious universities and journals throughout the world.

    • Reefer slackness: Does marijuana reduce motivation?Does popular belief that cannabis reduces motivation hold true? Researchers investigate across two studies, yielding surprising findings. 2 Sep 2016
    • Zika treatable with existing drugs, says breakthrough studyTwo drugs already approved for other reasons can stop Zika dividing in the body and causing the early fetal cell damage that leads to birth defects. 30 Aug 2016
  • Vitamin cocktails: An ethical dilemma of supply and demandThe Daily Meal report on intravenous vitamin therapies – also known as vitamin drip treatments – which have gained popularity recently. 26 Aug 2016
  • Cocaine addiction reversed in rats with novel compoundTreating rats with a compound that blocks TrkB receptors in the brain’s reward system was found to reverse signs of cocaine dependency, researchers report. 21 Aug 2016
  • New opioid as effective as morphine, without the side effectsResearchers have identified a drug candidate that is as effective as morphine for relieving pain, but without the harmful side effects of opioids. 18 Aug 2016
  • Is acetaminophen in pregnancy linked to behavioral problems in offspring?A study suggests that acetaminophen use, generally considered safe during pregnancy, may lead to a higher rate of behavioral issues in children. 15 Aug 2016
  • New asthma pill reduces troublesome symptomsIn what is hailed as a ‘game changer’ for future asthma treatment, a new study shows an asthma pill is effective in treating symptoms of the condition. 8 Aug 2016
  • Pharmacy on the go: Programmable device produces vaccines on demandA device that acts as a portable pharmacy for use in remote areas of the world has been developed as a cost-effective solution for on-demand treatments. 30 Jul 2016

    Further reading in this category

  • ‘Generic’ biologic drugs appear comparable to brand-name counterparts 3 Aug 2016
  • Investigation reveals how the NHS is impeding access to high priced drugs 29 Jul 2016
  • Acetaminophen: Is it as safe as we think? 27 Jul 2016
  • TSRI team finds potential drug candidates that could intervene in deadly diseases 25 Jul 2016
  • Pharmacogenetics experts establish common vocabulary in bid to advance precision medicine 22 Jul 2016
  • A toxic quick-change artist 19 Jul 2016
  • List of Medications Available for Diabetes 29 Jun 2016
  • Axial spondyloarthritis: Patients see sustained benefit with certolizumab pegol 28 Jun 2016
  • Plant kingdom provides 2 new candidates for the war on antibiotic resistance 22 Jun 2016
  • Research may point to new ways to deliver drugs into bacteria 20 Jun 2016
  • Scientists discover mechanism of thalidomide 17 Jun 2016
  • Rheumatoid arthritis patients experience long-term benefits with new drug 16 Jun 2016
  • Experimental drug shows promise against deadly MRSA infections 15 Jun 2016
  • New antiviral drugs could come from DNA ‘scrunching’ 10 Jun 2016
  • Recurrent C. diff infection reduced for high-risk patients in new trials 7 Jun 2016
  • Genetic approach could help identify side-effects at early stages of drug development 2 Jun 2016
  • Opioids might worsen chronic pain, study finds 31 May 2016
  • Harnessing nature’s vast array of venoms for drug discovery 25 May 2016
  • Cutting-edge findings in cannabis research 20 May 2016
  • Making injectable medicine safer 20 May 2016
  • Drug resistance ‘could kill 10 million people annually’ 19 May 2016
  • More potent, inexpensive gene silencing agents described in Nucleic Acid Therapeutics 13 May 2016
  • Heartburn drug prematurely ages blood vessels 11 May 2016
  • Therapeutic substitution could help reduce money spent on prescription drugs 9 May 2016
  • Prostate cancer: new drugs show promise against aggressive, resistant forms 3 May 2016
  • New European policy recommendations on cytotoxic drugs 3 May 2016
  • New molecule-building method from TSRI opens up vast realm of chemistry for pharma and other industries 25 Apr 2016
  • The European Parliament calls on the Commission to boost manufacturing and export of EU generic and biosimilar medicines 22 Apr 2016
  • Precision medicine: Is it becoming a reality for childhood cancer? 21 Apr 2016
  • Newly identified host defense mechanism protects cells from viral infection 21 Apr 2016
  • Micro heart muscle created from stem cells 21 Apr 2016
  • EU physicians prefer greater detail in the labelling of biosimilars 20 Apr 2016
  • Cracking the Zika mystery 20 Apr 2016
  • Rare pediatric cancer infantile fibrosarcoma (IFS) successfully treated with new targeted therapy 20 Apr 2016
  • Researchers find method that could resurrect an abandoned pancreatic cancer targeted drug 19 Apr 2016

    Looking for older articles? Browse our archive. or try our search .

  • Gmp pharma #pharmaceutical #science #jobs

    #gmp pharma


    GMP Question and Answers

    Why is GMP important?

    Poor quality medicines are not only a health hazard, but a waste of money for both governments and individual consumers.

    Poor quality medicines can damage health

    A poor quality medicine may contain toxic substances that have been unintentionally added.
    A medicine that contains little or none of the claimed ingredient will not have the intended therapeutic effect.

    GMP helps boost pharmaceutical export opportunities

    Most countries will only accept import and sale of medicines that have been manufactured to internationally recognized GMP. Governments seeking to promote their countries’ export of pharmaceuticals can do so by making GMP mandatory for all pharmaceutical production and by training their inspectors in GMP requirements.

    What is GMP?

    Good manufacturing practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product. The main risks are: unexpected contamination of products, causing damage to health or even death; incorrect labels on containers, which could mean that patients receive the wrong medicine; insufficient or too much active ingredient, resulting in ineffective treatment or adverse effects. GMP covers all aspects of production; from the starting materials, premises and equipment to the training and personal hygiene of staff. Detailed, written procedures are essential for each process that could affect the quality of the finished product. There must be systems to provide documented proof that correct procedures are consistently followed at each step in the manufacturing process – every time a product is made. WHO has established detailed guidelines for good manufacturing practice. Many countries have formulated their own requirements for GMP based on WHO GMP. Others have harmonized their requirements, for example in the Association of South-East Asian Nations (ASEAN), in the European Union and through the Pharmaceutical Inspection Convention.

    Is GMP necessary if there is a quality control laboratory?

    Yes. Good quality must be built in during the manufacturing process; it cannot be tested into the product afterwards. GMP prevents errors that cannot be eliminated through quality control of the finished product. Without GMP it is impossible to be sure that every unit of a medicine is of the same quality as the units of medicine tested in the laboratory.

    Can manufacturers afford to implement GMP?

    Yes. Making poor quality products does not save money. In the long run, it is more expensive finding mistakes after they have been made than preventing them in the first place. GMP is designed to ensure that mistakes do not occur. Implementation of GMP is an investment in good quality medicines. This will improve the health of the individual patient and the community, as well as benefiting the pharmaceutical industry and health professionals. Making and distributing poor quality medicines leads to loss of credibility for everyone: both public and private health care and the manufacturer.

    WHO works to strengthen GMP

    WHO GMP guidelines are available online. If you require more information, please contact the WHO representative in your country, your WHO regional office or WHO headquarters in Geneva.


    Former Pharmaceutical Company Employees Arrested For Participating In Fentanyl Kickback Scheme #elixir #pharma

    #pharmaceutical companies in nyc


    Justice News

    Former Pharmaceutical Company Employees Arrested For Participating In Fentanyl Kickback Scheme

    Preet Bharara, the United States Attorney for the Southern District of New York, Diego Rodriguez, Assistant Director-in-Charge of the New York Field Office of the Federal Bureau of Investigation (“FBI”), and Scott Lampert, Special Agent in Charge of the U.S. Department of Health and Human Services, Office of Inspector General’s (“HHS-OIG”) New York Region, announced that JONATHAN ROPER, a former District Manager at a pharmaceutical company (“Pharma Company-1”), and FERNANDO SERRANO, a former sales representative at Pharma Company-1, were charged today with violating the Anti-Kickback Statute in connection with their participation in a scheme to pay doctors thousands of dollars to participate in sham educational programs in order to induce the doctors to prescribe millions of dollars’ worth of a fentanyl-based sublingual spray manufactured by Pharma Company-1 (the “Fentanyl Spray”). ROPER was arrested this morning by FBI agents on Long Island, and SERRANO was arrested this morning by FBI agents in New Jersey. They will be presented before U.S. Magistrate Judge Kevin N. Fox in Manhattan this afternoon.

    Manhattan U.S. Attorney Preet Bharara said: “Fentanyl is an incredibly dangerous and highly addictive drug that is finding its way into, and destroying, too many lives in our communities. Because of its deadly power, its legitimate prescription faces significant and severe restrictions. Yet, as alleged, former drug company employees Jonathan Roper and Fernando Serrano corruptly induced doctors to prescribe millions of dollars’ worth of Fentanyl through thousands of dollars in kickbacks disguised as phony educational programs. As alleged, Roper and Serrano helped feed this devastating surge of opioid addictions by tapping into another age-old addiction, greed.”

    FBI Assistant Director Diego Rodriguez said: “This case should be something the medical industry and the general public should pay close attention to because it’s one of the reasons we’re experiencing an epidemic of overdoses and deaths in this country. Not only did the defendants in this case allegedly bully sales reps into pushing this highly addictive drug, they paid doctors to prescribe it to patients. The more prescriptions written, the more money the doctors made. Instead of seeing a way to help people who are dealing with extreme pain, they allegedly saw a huge payday that potentially put people’s lives in danger.”

    HHS OIG Special Agent in Charge Scott J. Lampert said: “We expect drug company representatives to be part of the prescription drug abuse solution – not part of the problem, as alleged in this case. We will continue to investigate kickback arrangements, which can undermine impartial medical decision-making and worsen the overuse of opioids in this country.”

    According to allegations in the Complaints unsealed today in Manhattan federal court:[1]

    Fentanyl is a synthetic opioid that is classified as a Schedule II controlled substance and is approximately 100 times more potent than morphine as an analgesic. Because of the risk of misuse, abuse, and addiction associated with prescription products like the Fentanyl Spray, only doctors who have enrolled in a mandated U.S. Food and Drug Administration (“FDA”) program and completed necessary training are permitted to prescribe the Fentanyl Spray.

    Pharma Company-1’s Fentanyl Spray was approved by the FDA in or about January 2012, solely for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent pain. The Fentanyl Spray is the only FDA-approved product that Pharma Company-1 currently has on the market. Pharma Company-1 reported approximately $330 million in net revenue from the Fentanyl Spray in 2015.

    In order to market the Fentanyl Spray, Pharma Company-1 established a program purportedly to educate healthcare professionals about the Fentanyl Spray (the “Speaker Program”). Doctors selected as speakers at these Speaker Programs by Pharma Company-1 (“Speakers”) were compensated for purportedly providing educational presentations to a peer-level audience of healthcare professionals using a preapproved PowerPoint presentation. In reality, however, many of the Speaker Programs that ROPER and SERRANO organized and attended were predominantly social gatherings at high-end restaurants in Manhattan that involved no education regarding the Fentanyl Spray and no slide presentation at all. Many of the Speaker Programs also lacked an appropriate audience of healthcare professionals. In order to make these Speaker Programs appear legitimate, sign-in sheets for these Speaker Programs – including Speaker Programs organized by ROPER and SERRANO – were frequently forged by adding the names and signatures of doctors to sign-in sheets who had not, in fact, been present at the Speaker Program. Repeat attendees were also commonplace at Speaker Programs organized by SERRANO. In numerous instances, all of the attendees at Speaker Programs organized by SERRANO had previously attended Pharma Company-1 Speaker Programs. Because all legitimate Speaker Programs required use of the same preapproved slide presentation, there was no educational purpose for healthcare professionals to attend Speaker Programs on a repeated basis.

    While employed at Pharma Company-1, ROPER and SERRANO were each involved in organizing Speaker Programs for two Manhattan-based doctors (“Doctor-1” and “Doctor-2”), among other doctors. Doctor-1 and Doctor-2 were frequently the purported Speakers at sham Speaker Programs that were social in nature and lacked an educational component. Doctor-1 and Doctor-2 were highly compensated by Pharma Company-1 for acting as Speakers. In 2014 alone, Doctor-1 and Doctor-2 received over $147,000 and $112,000, respectively, in Speaker Program fees. During this same time period, Doctor-1 and Doctor-2 were also two of the largest prescribers of the Fentanyl Spray in the United States. In 2014 alone, Doctor-1 and Doctor-2 prescribed, respectively, over $3 million and over $2 million worth of the Fentanyl Spray that was reimbursed by various private insurance companies, and over $1 million worth of the Fentanyl Spray that was reimbursed by Medicare.

    It was well understood among Pharma Company-1 employees that doctors were selected as Speakers in order to induce these doctors to prescribe large quantities of the Fentanyl Spray, and ROPER explicitly instructed the sales force he supervised that this was the case. For example, on or about May 6, 2014, ROPER sent an email to certain sales representatives in which he expressed displeasure that certain doctors who were Speakers were not prescribing sufficient quantities of the Fentanyl Spray:

    Where is the ROI [Return on Investment]. All prescribers from this team that are on this list are [Pharma Company-1] speakers. We invest a lot of time, $, blood, sweat, and tears on “our guys” and help spreading the word on treating BTCP [breakthrough cancer pain]. We hire only the best of the best to be apart [sic] of our speaker bureau and dropping script counts is what we get in return?

    This is a slap in the face to all of you and is a good indication as to why NONE of you are climbing in the rankings this quarter. DO NOT be afraid to set your expectations and make them crystal clear as to what they are before, during, and after HIRING these priviliged [sic] set of docs who are fortunate enough to be a part of the best speaker bureau in the market in the world of BTCP [breakthrough cancer pain]. Please handle this immediately as funding will not be given out to anymore [sic] “let downs” in the future. Thanks. $$$$

    ROPER decided which doctors would be allocated Speaker Programs in the sales territory that included New York City. ROPER instructed one sales representative that a Speaker would receive fewer Speaker Programs in the future because ROPER was not pleased with the quantity of Fentanyl Spray prescriptions this doctor was writing. ROPER informed the sales representative that he wanted to hit the doctor “in his pocket” in order to try to cause the doctor to start writing more Fentanyl Spray prescriptions. ROPER also once instructed this same sales representative to offer cash to a medical professional in order to induce this medical professional to prescribe the Fentanyl Spray.

    ROPER, 37, of Commack, New York, and SERRANO, 30, of Manalapan, New Jersey, are each charged with one count of conspiracy to violate the Anti-Kickback Statute and one count of violating the Anti-Kickback Statute. Each of the two counts carries a maximum term of five years in prison. The maximum potential sentences are prescribed by Congress and are provided here for informational purposes only, as any sentencing of the defendants will be determined by the judge.

    The charges contained in the Complaints are merely accusations, and the defendants are presumed innocent unless and until proven guilty.

    Mr. Bharara praised the investigative work of the FBI and the HHS-OIG.

    The case is being prosecuted by the Office’s Complex Frauds and Cybercrime Unit. Assistant U.S. Attorney Noah Solowiejczyk is in charge of the prosecution.

    [1] As the introductory phrase signifies, the entirety of the text of the Complaints and the description of the Complaints set forth herein constitute only allegations, and every fact described should be treated as an allegation.